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ACUTE RENAL FAILURE IN HAEMOTOXIC 
SNAKE ENVENOMATION 
 
INTRODUCTION: 
 Acute renal failure is characterized by a deterioration in the renal function 
over a period of hours to days, resulting in the failure of the kidney to excrete 
nitrogenous waste products and maintain fluid and electrolyte homeostasis.  
               In India about 60% cases of acute renal failure occurs in medical wards, 
20% in the surgical side and remaining 20% in obstetrical conditions.  In medical 
settings diarrhoeal disorders account for 15% of cases, snakebites for 10% of cases, 
another 5-10% with poisonings such as copper sulphate. 
 
              Snakebite envenomation is a frequently encountered problem in tropical 
countries like India, especially in the remote rural areas of south India.   Most of the 
victims are middleaged farmers.  The only specific treatment of a poisonous 
snakebite is antivenom.  Serotherapy must be initiated as early as possible to save the 
life and to avert complications such as renal failure.  The main object of this study is 
to highlight the evaluation of renal failure among the snake envenomation and the 
consequences their after. 
 
 
 
 
  
 
AIM OF THE STUDY 
 
¾ To find out the incidence and etiology of acute renal failure among the snake 
envenomation cases. 
¾ To evaluate renal failure in cases of snake envenomation with relation to age, 
sex, tourniquet application, onset of treatment since the snakebite,and 
preexisting anaemia. 
¾ To study the time of onset of renal failure since the snakebite and the role of 
supportive therapy and haemodialysis in the management of acute renal 
failure. 
¾ To study the bleeding diathesis and any other complications and unsual 
presentations following the envenomation. 
¾ To find out the incidence and probable cause of death among snake 
envenomation cases and the time of death after the snake bite. 
 
 
 
 
 
REVIEW OF LITERATURE 
 
SNAKES: 
               It belongs to phylum–chordate, class-ophidia reptilia, order-squamata, 
suborder-ophidia. OPHIDIA means SNAKES (or) SERPENTS. 
              Ophitoxaemia is the rather exotic term that characterizes the clinical 
spectrum of snakebite envenomation. Of the 2500-3000 species of snakes distributed 
world wide, about 500 are venomous. (13) Based on the morphological 
characteristics including arrangement of scales /dentition /osteology /myology 
/sensoryorgans etc., snakes are categorized into families.  The families of venomous 
snakes are Atractaspididae, Elapidae, Hydrophidae and Viperidae. 
               The major families in the Indian subcontinent are Elapidae, which includes 
Common Cobra, King Cobra and Krait, Viperidae, which includes Russell’s viper, 
Pit Viper and Saw Scaled Viper and Hydrophidae, which are the sea snakes. Of the 
52 poisonous species identified in India, majority of bites and consequent mortality 
is attributable to only 5 species viz ophiophagus Hannah (King Cobra), NajaNaja 
(Common cobra) Daboia Russelli (Russell’s viper), Bungarus caeruleus (krait) and 
Echis carinatus. (Saw-scaled viper) 
                The snakes whose bites are known to cause acute renal failure in India 
includes, Russell Viper, SawScaled Viper. Since, majority of snakes are non-
venomous, it is important to know the anatomical differences between venomous and 
nonvenomous snakes. This will help to obviate needless administration of potentially 
harmful antivenom in every case of snakebite.     
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 IDENTIFICATION AND ANATOMY OF HAEMOTOXIC SNAKES  
Saw-Scaled viper 
 Scientific Name                     : Echis carinatus. 
 Other common Names         : Carper viper, “Phoorsa” 
 Geographical distribution   : All over India (especially plains  and deserts) 
 Physical characteristics:       The Saw Scaled Viper is a small snake, about 1 
½ to 2 feet long, and is usually brown in colour. There is a wavy white line along the 
entire length of each flank, while diamond-shaped markings extend over the back, 
numbering usually 25 to 30. The head is triangular with small scales. A characteristic 
whitish, arrow shaped (or) Crow’s Foot mark is often present on the head.  
 The Saw Scaled Viper is named as such because its scales are serrated. When 
agitated, it throws itself into a double coil (in the manner of a “ Figure of eight”) and 
rubs the coils together vigorously, producing a harsh, rasping sound, akin to the 
sound of a sandpaper being scraped over a rough surface. At the sametime, it also 
hisses loudly by exhaling forcefully through the nostrils. The Echis is an aggressive 
snake and may bite on the slightest provocation. The pupils are vertical and it is 
viviparous. 
Habitat:  These snake prefer desert regions, and is often found basking in the sun 
during the daytime, among rocks or in sandy soil. It may enter human habitation 
especially tents, in search of it`s prey. 
Life span : 2 to 5 years or more. 
Nature of venom :Vasculo and haemotoxic. 
Russell`s Viper 
Scientific name : Daboia russelli, Vipera russelli 
Geographical distribution : All over India  
Physical characteristics: 
 This is a brownish, stout snake, growing up to several feet in length. The head 
is triangular, with a ‘V’shaped mark (apex pointing forward) and is covered with 
small scales. There are 3 rows of chained dark spots over the entire body. Pupils are 
vertical. Fangs are long, channelised, and hinged, being erected at the time of 
striking. The Russell’s viper is known to hiss loudly when agitated and is viviparous. 
Nature of venom   : Vasculo  and haemotoxic.  
Pit viper 
 The head is covered with shields and a pit is present in between the eyes and 
the nostrils, which has a thermo receptor. 
Snake Venom (21) 
Source: It is the saliva secreted by the modified parotid glands of a venomous snake. 
Cobra venom is faint transparent yellow and is slightly viscous. Russell’s viper 
venom is white or yellow. The concentration of venom shows diurnal and seasonal 
variation. Bites inflicted at nights and immediately after hibernation are the most 
severe. Venom travels in the body through lymphatics and superficial veins. (21). 
 Snake venom, the most complex of all poisons is a mixture of enzymatic and 
nonenzymatic compounds, as well as other nontoxic proteins, carbohydrates and 
metals. There are over 20 different enzymes including phospholipases A2, B, C, D, 
hydrolases, phosphatases (acid as well as alkaline), proteases, esterases,  
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acetylcholinesterase, transaminase, hyaluronidase, phosphodiaesterase, nucleotidase, 
ATPase and nucleosidases. (DNA &RNA). (1) 
 The nonenzymatic components are loosely categorized as neurotoxins and 
haemorrhagens (16). Different species have differing proportions of most if not all of 
the above mixtures. This is why poisonous species were formerly classified 
exclusively as neurotoxic, haemotoxic or myotoxic. 
Pathophysiology of ophitoxaemia  
 The pathophysiologic basis for morbidity and mortality is the disruption of 
normal cellular functions by these enzymes and toxins. Some enzymes such as 
hyaluronidase disseminate venom by breaking down tissues barriers. (9). 
           The variation of venom composition from species to species explains the 
clinical diversity of ophitoxaemia. There is also considerable variation in the relative 
proportions of different venom constituents within a single species throughout its 
geographical distribution, at different seasons of the year and as a result of ageing.  
 Various venom constituents have different modes of action. Ophitoxaemia 
leads to increase in the capillary permeability which may cause loss of blood and 
plasma volume into the extravascular space.(13) This accumulation of fluid in the 
interstitial space is responsible for edema. The decrease in the intravascular volume 
may be severe enough to compromise circulation and lead on to shock. Snake venom 
also has direct cytolytic action causing local necrosis and secondary infection, a 
common cause of death in snakebite patients. The venom of Elapidae may also have 
direct neurotoxic action leading to paralysis of the muscles and respiratory failure, 
cardiotoxic effect causing cardiac arrest, myotoxic and nephrotoxic effects. 
Ophitoxaemia also causes alteration in the coagulation activity leading to bleeding 
which may be severe enough to kill lthe victim. PhospholipaseA2 in Russell Viper 
Venom induce spheroechinocytosis which may produce hypoxic cell injury 
(Napathorn .S.) (66).  
EPIDEMIOLOGY OF SNAKE BITE (13) 
 Snakebite remains a public health problem in many countries even though it is 
difficult to be precise about the actual number of cases. It is estimated that the true 
incidence of snake envenomation could exceed 5 million per year. About 1,00,000 of 
these develop severe sequelae. The global disparity in the epidemiological data 
reflects variations in health reporting accuracy as well as the diversity of economic 
and ecological conditions. 
 To complicate matters further, accurate records to determine the exact 
epidemiology or even mortality in snakebite cases are also generally unavailable (1). 
Hospital records fall far short of the actual number owing to dependence on 
traditional healers and practitioners of witchcraft etc. It has been reported that in 
most developing countries, upto 80% of individuals bitten by snakes first consult 
traditional practitioners before visiting a medical centre. Owing to the delay several 
victims die during transit to the hospital. 
  According to Reid, venomous snakes have two types of bites, the first type 
being a business bite inflicted when the snake is after a prey. In this case, a large 
amount of venom is injected and to victim dies rapidly. The second type of bite is as 
a matter of defence or warning and little or no venom is injected, the snake’s object 
being to escape. When a venomous snake, bites human beings, it generally uses the 
second type of bite. Therefore, over 50% of the victims have minimal or no 
poisoning and only 25% develop serious systemic symptoms. 
While snakebite is observed in all age groups the large majority (90%) are in 
males aged 11-50 years. The predominance of male victims suggests a special risk of 
outdoor activity (14). The high incidence of snakebite between 04.00 hours to mid 
night corresponds well with the period of maximum outdoor activity observed in 
most studies. The incidence of snakebite shows a distinct seasonal pattern closely 
related to rainfall and temperature which compels the reptiles to come out of their 
shelter.(14) 
A large number of bites occur in fields, most individuals are unable to spot 
the snake due to tall grass and crops. The observation that the most frequent site of 
bite is the lower extremity suggests that in most cases the snake is inadvertently 
trodden upon. Among host factors, people involved in occupations and lifestyles 
requiring movement in dense undergrowth or undeveloped land, are the worst 
affected. These include farmers, herders, and hunters and workers on development 
sites. 
Morbidity and mortality resulting from snakebite envenomation also depends 
on the species of snake involved, since estimated “ Fatal dose” of venom varies with 
species. In the Indian seething, almost 2/3 of bites are attributed to Saw Scaled Viper 
(as high as 95% in some areas like Jammu) (18), about ¼ to Russell’s Viper and 
small proportions to Cobra & Kraits.Among the various species, the average yield 
per bite in terms of dry weight of lyophilized venom is 60 mg for Cobras, 63 mg for 
Russell’s Viper, 20 mg for Krait and 13mg for Saw Scaled Viper. 
The respective “Fatal doses” are much smaller viz 12mg for Cobra, 15mg for 
Russell’s Viper, 6 mg for Krait and 8 mg for Saw Scaled Viper.(21) However, 
clinical features and outcomes are not as simple to predict because every bite does 
not result in complete envenomation. (22). Epidemics of snakebite following floods 
owing to human and snake population getting concentrated together have been noted 
in Pakistan, India and Bangladesh. 
How serious a problem is snakebite in INDIA?  
Swaroop reported about 2,00,000 bites and 15,000 deaths in INDIA due to 
snakebite poisoning as far back as 1954 (6). Based on an epidemiological survey of 
28 villages with a total population of nearly 19,000 individuals in Burdwan district 
of West Bengal state, Hati et al worked out an annual incidence of 0.16% and 
mortality rate of 0.016% per year. 
Maharashtra, has the highest incidence, reporting 70 bites per 1,00,000 
population and mortality of 2.4per 1,00,000 per year.(11) The other states with a 
large number of snake bites cases include West Bengal, Tamilnadu, Utter Pradesh 
and Kerala(1). 
The Hindu – Magazine June 13 2004: 
Actually we do not have upto date data, as the statistics are not very clear or 
simply absent. The latest survey was done in 1972 by Dr. Sawai and Dr.Homma of 
the JAPAN Snake Institute, the report concluded that about 10% of deaths are of the 
victims who come to the hospital and about 90% die outside, having gone for other 
remedies like manthra and magic. It is very different now after 30 yrs. 
Based on the recent preliminary survey that Janaki and Romulus Whitaker did 
in Kerala, West Bengal and Rajesthan, they found the awareness about ASV is much 
higher now than it was 1972 and majority of snakebite victims now come to 
hospitals. Actual Incidence of snakebite is increasing, by destroying the forest and 
creating agricultural lands, we are increasing the prey base of the snake that is frogs 
and rats. So, it attracts a lot of snakes. Humans going into the field every morning 
and coming out in the evening, is just the time when the snakes are active. Thus, the 
chance of an encounter between farmer and snake is very high. 
It is not correct to say that if a snake had bitten in the recent past, its poison is 
less in the subsequent bite. A snake never runs out of venom and it does not inject all 
the venom from the sac. 
Status of venomous snakes in India 
Tamil Nadu, Kerala, Rajesthan and West Bengal where the incidence of 
snakebite is high, where different snakes are responsible for the bites. In Rajesthan it 
was the Saw Scaled Viper, in northern Kerala, it was mainly the bite of Russell’s 
viper and in Tamil Nadu, it is a mixture of Cobra and the Krait. In Bengal it was a 
mix of all of the “Big four” except Saw Scaled Viper. 
Cobra flourish as long as there are rice fields. There they feed mainly on the 
mole rat. (Varapu eli – in Tamil). They live and lay their eggs in the rat burrow 
network, Kraits also get by very well in rice fields because they like the plentiful 
small rodents such as field mouse (sundeli –in Tamil) and rock mouse.(kallueli) We 
have found a lot of Kraits in the mounds of earth and rubble near wells .The 
Russell’s Viper lives in the rocky outcrops and hedgerows of cactus and other bush. 
There, on the high ground they have a plentiful supply of common gerbil (velleli –in 
Tamil)  
CLINICAL MANIFESTATIONS 
 The clinical manifestations of snakebite occur in a wide spectrum with some 
bites resulting in minimal or no symptoms at all, while others are severe enough to 
result in systemic manifestations and even death. 
1.  SNAKE BITE WITH  NO MANIFESTATIONS 
 The most obvious explanation for a confirmed snakebite but no clinical 
manifestations is bite by a non-poisonous species. However, it is well documented 
that a large number of poisonous species also often do not cause symptoms. 
 In a study of 432 snakebites in North India, Banerjee noted that 80% of 
victims showed no evidence of envenomation (1). This figure correlates almost 
exactly with a more recent observation from Brazil (24). Reid also states that over 
50% of individuals bitten by potentially lethal venomous snakes escape with hardly 
any features of poisoning.(22)This is corroborated by saini’ s study of 200 cases in 
Jammu region in India, in which only 117 showed symptoms and signs of 
envenomation (19). From the relatively low frequency of poisoning following 
snakebites, it has been suggested that snakes are on the defensive when biting 
humans and seldom inject much venom (25). Other possible explanations include a 
bite without release of venom (dry bite). There are also cases wherein venom is 
spewed in to the victim`s body as the snake attempts to bite, there by reducing the 
overall quantity of venom in the blood stream. Other protective factors include the 
layers of clothing or boot leather through which the snake sometimes strikes.(27). 
2. LOCAL MANIFESTATIONS 
 With the possible exception of the psychological trauma of being bitten, local 
changes are the earliest manifestations of snakebites (28). Features are noted with in 
6-8 minutes but may have onset upto 30 minutes (21,29). Local pain with radiation 
and tenderness and the development of small reddish wheal are the first to occur. 
This is followed by oedema (16), swelling, (due to increased vascular permeability) 
appearance of bullae – all of which can progress quite quickly and extensively even 
involving the trunk (19). The factors responsible for increased vascular permeability 
are proteases,\ phopholipases,\ membrane damaging polypeptide toxin,\ 
hyaluronidase,\and endogenous autocoid (histamine, 5HT and kinin). In Viperbites 
due to increased vascular permeability leading to pulmonary edema, serous effusion, 
conjunctival and facial oedema, haemoconcentration are reported. Tingling and 
numbness over the tongue, mouth and scalp and paraesthesias around the wound 
occur mostly in viper bites. (21). Local bleeding including petechial and / or purpuric 
rash is also seen most commonly with this family. Regional lymphadenopathy has 
been reported as an early and reliable sign of systemic poisoning. (30) For local 
tissue necrosis, direct action of myotoxic, cytolytic factors possibly by polypeptide 
toxin, and ischaemia caused by thrombosis, external compression by tourniquet or 
compression of arteries by swollen muscle with in tight facial compartments also 
contribute. Generally Elapid bites result in early wet type gangrene whereas Vipers 
cause dry gangrene of slower onset; though one of the authors (JLM) has also seen 
the reverse pattern. 
 
 
 
LOCAL MANIFESTATIONS 
 
 
 
 
 
 
 
 
 
        CELLULITIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
            CELLULITIS WITH  
         GANGRENE 
 
 
 
 
 
 
 
 
 
 
 
 
            CELLULITIS WITH  
                 ECCHYMOSIS 
 
 
 
 
 
 3. Systemic Manifestations  
 As mentioned previously, the most common and earliest symptom following 
snakebite (Poisonous or Non poisonous) is fright (28) particularly of rapid and 
unpleasant death.(21) Owing to fright, a victim attempts  “flight” which 
unfortunately result in enhanced systemic absorption of venom.  These emotional 
manifestations develop extremely rapidly and may produce psychological shock and 
even death.  Fear may cause also transient pallor, sweating and vomiting. 
 Other systemic manifestations depend upon the pathophysiological changes 
induced by the venom of that particular species. 
i) Hypotension and Shock  
 Profound hypotension is part of the acute pharmacological syndrome, which 
can occur within minutes in Viper bite.  It may be due to (a) release of vasodilating 
autocoids, oligopeptides, inhibition of bradykinin deactivating enzymes and angio 
tensinogen converting enzymes.  b) Leakage of plasma or blood in to the bitten limb 
and elsewhere (or) massive GI bleeding may cause hypovolaemia   c) Vasodilatation 
especially of splanchnic vessels.  d) Direct myocardial action may contribute to 
hypotension after viper bite. 
ii) Bleeding and clotting disturbances  
 Snake venom can cause haemostatic defect in different ways.  Its venom 
procoagulant can activate intravascular coagulation and produce consumption 
coagulopathy leading to incoagulable blood and thrombocytopenia.  Venoms also 
can cause qualitative and quantitative defects in platelet function. (39) Spontaneous 
systemic bleeding is attributable to distinct venom component, haemorrhagins that 
damage vascular endothelium. 
iii) Intravascular haemolysis  
 The Russell’s Viperbite may be associated with massive intravascular 
haemolysis (37).  Evidence of mild microangiopathic haemolysis is sometimes found 
in patients with severe bleeding and clotting disturbances. 
iv) Neurotoxicity  
 Neurological deficits can occur following Viperbites.  It is usually due to 
intracerebral haemorrhage (6) and subarachnoid haemorrhage as a result of depletion 
of clotting factors. 
v) Renal failure  
 It is one of the common complications of Viper bite and one of the major 
causes of death (41).  The possible mechanisms of acute tubular necrosis are 
prolonged hypotension, DIC, direct nephrotoxic action of venom, haemoglobinuria, 
myoglobinuria and hyperkalemia. In a series of 40 viper bites, renal failure was 
documented in about a third. (42) The extent of renal abnormality in them correlated 
well with degree of the coagulation defect; however in a majority renal defects 
persisted for several days after the coagulation abnormalities normalized: Suggesting 
that multiple factors are involved in venom induced ARF. 
vi) Cardiotoxicity  
 Cardiotoxic features include tachycardia, hypotension and ECG changes.  
Cardiotoxicity occurs in about 25% viperine bites and include rate, rhythm, and 
blood pressure fluctuations. (32) In addition, sudden cardiac standstill may also 
occur owing to hyperkalemic arrest. 
 vii) Rhabdomyolysis  
 It is a feature of Sea Snakes and Srilankan Viper.  The patient may die of 
bulbar and respiratory muscle weakness from acute hyperkalemia or later due to 
renal failure. 
4.Rare Systemic Manifestations  
Non- dyselectrolytemic acute myocardial infarction has been reported. (33) 
There is a single case report of non-bacterial thrombotic endocarditis following viper 
bite (35)(PGI chandigarh, 1998). One case of ventricular tachycardia following 
Russell’s viper bite has been reported from Thailand (2005) and successfully treated 
with cardioversion and Amiodarone. (91) Snake bite induced ischaemic colitis with 
colonic stricture complicated by DIC has been reported from Japan 1995. (88) One 
case of snakebite presenting as acute myocardial infarction, ischaemic CVA, ARF 
and DIC has been reported from Nizam’s Institute, Hyderabad 2000. (83) One 
patient had developed hypopituitarism after viperine envenomation. (75) 
 A healthy young male developed motor aphasia and right- sided hemiplegia 
within 2 hours of viper bite. CT brain revealed a left frontal lobe infarction (Panicker 
J.N. Kerala, JAPI 2000). (49) One patient had developed acute flaccid paraplegia as 
a result of dorsal spinal cord involvement following viper bite (Singh.S. PGI 
Chandigarh 2002)(34) 
Dr. Rathod K, King Edward VII memorial hospital, Mumbai 2003(71) report 
the CT findings in a case of Russell’s viper bite resulting in hemo peritoneum, which 
to the best of our knowledge has not been reported in the literature. 
Multiple thrombotic occlusions of vessels in the form of multiple cerebal 
infarctions, digital gangrenes and ischaemic organs after Russell’s viper envenoming 
has been reported. (79). Bilateral thalamic haematoma (45) and hysterical paralysis 
(46) have also been reported.                                                                            
5.Unusual manifestations of ophitoxaemia 
a. Delayed manifestations  
Authors are all uniform in their opinion that delayed onset of signs is rare.  In 
their series of 56 cases, Saini et al documented 4 patients who had normal clinical 
and laboratory coagulation profile at admission shortly following bite, but started 
bleeding as late as 4-6 days after the bite. (28) 
 The possible explanation for these manifestations is that local blebs constitute 
a venom depot, which is suddenly released into the blood stream, especially when 
the wound is handled surgically. (29) Further, these depots are generally inaccessible 
to antivenom. Reid has noted that haemorrhage in the brain may be delayed up to 
one week after bite. (28) Kumar et al have reported a singular occurrence of 
unconsciousness 6 days after an individual was bitten who remained symptom free 
for the first 5 days. (53) 
b. Recurrent manifestations  
 Recurrent manifestations have not been discussed in most of the published 
literature.  The only record is Warrell’s assertion that signs of systemic 
envenomation may recur hours or even days after initially good response to 
antivenom.  This has been explained by ongoing absorption of venom from the 
blood, which has a half- life of 26-95 hrs. (17) He therefore suggests daily evaluation 
of patients for at least 3-4 days. 
 
c. Manifestations of Snake bite not because of toxemia  
 Cases have been reported wherein the clinical manifestations of snakebite are 
not because of the poisoning, but due to hypersensitivity. (27) This has been noted, 
irrespective of a history of previous bite by the same or different species.  Such 
patients may manifest with anxiety, cutaneous sensitivity or tightness in the throat.  
They may also present with features of anaphylactic shock. 
 
d .Toxemia without bite  
 Naja Nigricollis (Spitting Cobra) is a species which can eject venom with 
considerable accuracy even from a distance of 6-12 feet.(17) The venom is aimed at 
the victim’s eyes resulting in conjunctivitis and corneal ulceration.   
 
e. Bite by a killed snake  
 There are instances on record where in a recently killed snake and even those 
with severed heads have ejected venom into those handling them.  This is the basis 
for the absolute ban on handling and extreme caution in transportation, which is 
usually advocated for killed snakes. (17) 
 
Factors affecting severity and outcome in Ophitoxaemia  
 There are several agent, host, and environmental factors that modify the 
clinical presentation and resultant mortality of ophitoxaemia. 
 Host factors   
Children overall fare worse than adults owing to greater amount of toxin inj      
ected per unit body mass. (16) For the same age, individuals in a better state of 
health fare better than more debilited counter parts. (16) Patients bitten on the trunk 
face and directly in to the blood stream have a worse prognosis. (16) Reid however 
asserts that the age of the victim and part of body bitten have no relation to 
outcome.(29) 
Exercise and exertion following bite may result in systemic absorption of 
venom. This is why individuals who panic and free from the scene of bite generally 
have a worse outcome. (57) The protection afforded by layers of clothing or shoes 
sometimes mitigates the effects of envenomation to a considerable extent. (27) 
Sensitivity of individuals to venom naturally modifies the clinical picture. Victims 
who develop secondary infection at the site of bite fare worse than those uninfected. 
(57) 
Agent Factors  
The number and depth of the bites inflicted by the Snake is a relative index of 
the amount of venom injected. (16) Indirect evidence for this is also available by 
studying the volume of venom remaining in the glands and fangs. The condition of 
fangs, intact or broken is also an indirect indicator of amount of envenomation. The 
species of snake, which has bitten alters outcome since the amount of venom injected 
and the ‘Lethal dose’ varies with species. (21) 
The length of time a snake clings to its victim and the presence or absence of 
pathogenic organisms in its mouth is two other agent factors affecting outcome. 
The time of bite (day or night) and breeding habits of the snake are not related to 
outcome in anyway. (27) The size of snake does not appear to be related to the 
efficacy of envenomation since several small specimens also have lethal capacity. 
Environmental Factors  
 The nature of first aid and the time elapsed before administration is perhaps 
the single most important factor- affecting outcome. (27) 
Mortality 
 While there are many factors influencing the outcome in victims of snakebite, 
there is an over all agreement in the case fatality rate, generally varying from 2-10% 
(16, 47-51).  The mortality rate is higher in children owing to larger amount of toxin 
per kg body weight absorbed. (27) There is significantly higher mortality among 
victims who develop neurotoxicity. (47,51) On an average – Cobras and Sea snakes 
result in about 10% mortality (28) ranging from 5-15 hours following bite.  Vipers 
have a more variable mortality rate of 1-15% and generally more delayed. (Up to 48 
hours.)(22) 
Laboratory Aids in Ophitoxaemia  
 The laboratory serve rather poorly in the diagnosis of snakebite, with the 
exception of ELISA studies which are now available to identify the species 
involved, based on antigens in the venom. (22) These tests are expensive and not 
freely available hence of limited value, except for epidemiological study. (16) Radio 
immune assay (RIA) has been developed for detection of Russell’s viper venom in 
body fluids.   
1.Blood changes include anaemia, leucocytosis of neutrophils  > 20,000 
cells and thrombocytopenia among envenomation cases. 2.Peripheral smear may 
show fragmented RBC’s evidence of haemolysis – particularly in viperine bites. 
3.Haematocrit initially high because of haemoconcentration due to increased 
capillary permeability.  Subsequently fall in haematocrit due to bleeding. 4.Plasma 
fibrinogen less than 200mg, (16) FDP level more than 80 ug/ml, clotting time of 
more than 20 mints, prolonged prothrombin time, thrombocytopenia are the 
abnormality found in DIC. 
5.Among the metabolic changes, hyperkalemia and hypoxemia with 
respiratory acidosis, especially with neuroparalysis may be present. (16) In case of 
ARF, all features of azotemia are present. 6.Quality of clot formed may be a better 
indicator of coagulation capability than the actual time required for formation, since 
clot lysis has been observed in several patients who had normal clotting time. (19) 
7.Increased serum bilirubin level, urobilinogen in urine, black coloured 
urine seen in intravascular haemolysis.8.Urine Examination could reveal 
haematuria, proteinuria, haemoglobinuria, or myoglobinuria. 9.Blood CPK, 
aspartate amino transferase, pottassium, myoglobin all are increased in 
rhabdomyolysis.10.Serum cholesterol at admission has been found to correlate 
negatively with severity of envenomation.  It is more likely an indication of change 
in lipoprotein transport and metabolism as a result of phospholipase A2 in venom. 
(59) 11.The measure of urinary N – acetyl beta – D – glucosaminidase is earlier 
indicator of renal failure, even with in 2 hours of bite. 
12.ECG changes are generally non-specific and include alterations in rhythm 
(predominantly bradycardia) and atrioventricular block with ST segment elevation or 
depression.  T wave inversion and QT prolongation (1) have also been noted.   Tall T 
waves in lead V2 and patterns suggestive of acute myocardial infarction have been 
reported as well. (32) Cases who develop hyperkalemia manifest typical ECG 
changes. 
13.EEG changes have been noted in upto 96% of patients bitten by snakes. 
Starting with in hours of the bite.  Interestingly none of them showed any clinical 
features suggestive of encephalopathy.  These abnormal EEG patterns were picked 
up mainly in the temporal lobes. 14.USG abdomen for size of kidney and to find out 
the existence of renal disease. 15.CT brain for infarction and haemorrhage. 
Management of Ophitoxaemia  
 A review of literature pertaining to management of snakebite makes 
interesting reading, particularly with respect to traditional methods. (27) However 
even a brief review of these novel practices is beyond the scope of the present 
discussion.  Owing to the variables involved in therapy, an ideal prospective clinical 
trial will likely never be done. (61) 
1.First Aid  
 Most physicians are in disagreement with regard to nature, duration and even 
necessity of first aid.  Russell advises minimal wastage of time with first aid 
measures which often end up doing more harm than good. (27) 
It is felt that reassurance and immobilization of the affected limb with prompt 
transfer to a medical facility are the cornerstones of first aid care. (16,22) Most 
experts also advocate the application of a wide tourniquet or crepe bandage over the 
limb to retard the absorption and spread of venom. (16,28) The tourniquet should be 
tight enough to occlude the lymphatics, but not venous drainage. (1)  Though some 
also prefer to occlude the veins.  Enough space to allow one finger between the limb 
and bandage is most appropriate. Should the limb become edematous, the tourniquet 
should be advanced proximally. (16) 
Tourniquets should never be left in place too long for fear of distal avascular 
necrosis. (27) In a recent repot from Brazil, two cases were reported to have 
increased local envenoming subsequent to a tourniquet. (62) Efficacy of compression 
immobilization technique was studied in Immunology Research division, Yangon 
Myanmar 1994. (87) This technique effectively retard the spread of radio labeled 
Russell’s viper venom and Radioactive Na I 131 from the site of injection. 
Efficacy of Tourniquet as a first aid measure was disagreed by immunology 
research division, Rangoon, Burma (1987)(89) and Dept. of medical research, 
Yangon, Myanmar 2000. (69) 
It was formerly believed and therefore advocated that incision over the bite 
drains out venom. However, it has now been established from animal experiments 
that systemic venom absorption starts almost instantly; this form of ‘therapy’ is 
therefore being questioned. (27,28) Some experts suggest that longitudinal incision 
within fifteen minutes of the bite may be beneficial. (1) Suction of the local area, a 
staple of snakebite measurement in Indian Cinema, also has its advocates and 
detractors, while most have rejected it for its questionable efficacy. (63) There are 
others who advice this method on the grounds of rapidly removing a large amount of 
venom. (64) There is patented device, the sawyer extractor available in the U.K. for 
this purpose.  It’s suggested use has generated controversy with a series of letters to 
the Editor of NEJM justifying or condemning its use. (63,64) 
Reid has advised that the wound site be minimally handled.  Most authors 
recommend saline cleaning and sterile dressing. (28) Some however advise that the 
wound be left open. (1,29) There is disagreement over the use of drugs as part of first 
aid care.  It has been suggested that NSAID`S particularly aspirin may be beneficial 
to relieve local pain.  Russell however dissuades use of analgesia and in particular 
aspirin for fear of precipitating bleeding. (27) In Reid’s experience pain relief with 
placebo was as effective as NSAID`S. (22) Codeine may be useful in some cases. (1) 
Similarly there are proponents as well as opponents for use of sedatives. (27) 
Almost all experts agree that the offending snake must not be provoked 
further by attempts to capture or kill it. (27) This is for fear of provoking an already 
enraged reptile to strike again. 
2.Specific therapy – Antivenom  
Antivenoms are prepared by immunizing horses with venom from poisonous 
snakes and extracting the serum and purifying it. Antivenoms may be species 
specific (monovalent) or effective against several species (polyvalent). Monovalent 
is ideal, but the cost and non-availability, besides the difficulty of accurately 
identifying the offending species – makes its use less common. (17) 
 
a.Indication for use : 
 There are specific indications for use of antivenom. (11,17) Every bite even if 
poisonous species does not merit its use.  This caution against the empirical use of 
antivenom is due to the risk of hypersensitivity reactions. (28,29) Therefore, 
antivenom is indicated only if serious manifestations of envenomation are evident 
viz coma, neurotoxicity, hypotension, shock, bleeding, DIC, ARF, Rhabdomyolysis 
and ECG changes. (16) In the absence of these systemic manifestations, swelling 
involving more than half the affected limb, (1) extensive bruising or blistering and 
progression of the local lesions with in 30-60 minutes, pregnancy and in children are 
other indications. 
 
b.Dosage : 
 Despite widespread use of antivenom, there are virtually no clinical trials to 
determine the ideal dose. (68) The conventional practice is to base the initial dose on 
the severity of envenomation. 
 
 
 
 
 
 
 
 
Approximate Initial dose of antivenom 
Grade of severity Initial dose 
Minimal envenomation 
   Mainly local effects 
   No significant laboratory changes 
 
50 ml 
Moderate envenomation 
  Signs of envenomation extend beyond bite site 
  Significant systemic envenomation 
  Moderate laboratory changes 
 
100 ml 
Severe envenomation 
  Entire limb affected 
  Serious systemic envenomation 
  Very significant laboratory changes 
 
150 ml 
 
The antivenom is given intravenously; 5 ml / min, or diluted in isotonic fluid 
and infused over 30 to 60 minutes. Pregnancy is not a contraindication. Children 
require the same dose of antivenom (even more) as adults. Venepuncture sites must 
be dressed with pressure bandage. Repeat the initial dose of antivenom if, severe 
CVS or CNS symptoms, persists for more than ½ hour; or incoagulable blood 
persists for more than 6 hours after the first dose. It must be remembered that 
systemic envenoming can recur several days after an initial good response to 
antivenom. There is no fixed upper limit to the dose of antivenom to be 
administered. (14) Enormous doses have been given in some cases. 
c. Administration : 
The Freeze- dried powder is reconstituted with 10 ml of injection water or 
saline or dextrose. A test dose is administered on one forearm with 0.02 ml of 1:10 
solution intradermally.  Appearance of erythema or wheal greater than 10 mm within 
30 min is taken as a positive test.(16) 
Desensitization :  Begin with subcutaneous administration of 0.1 ml of 1:100 
solution, and increase the dose every 15 min as follows, 0.2 ml and 0.5 ml.  Repeat 
the same regimen with 1:10 solution and finally with undiluted antivenom. Since 
desensitization is a time consuming and laborious procedure, some investigators 
recommend an alternative method; it consists of IV administration of anti histamine 
followed by an infusion of a dilute solution of adrenaline. 
Antivenom is administered by the intravenous route (16) and never into finger 
or toes. (27) Some authors recommend that 1/3 to ½ the dose be given at the local 
site to neutralize venom there. (27) However animal experiments have established 
that absorption begins almost instantly from bite sites.  Besides this, systemic 
administration of antivenom has been shown to be effective at the local site as well.  
Therefore most experts do not advise local injection of antivenin. (27) 
Efficacy of intramuscular administration of antivenom followed by standard 
hospital management has also been evaluated and a definite reduction in the number 
of patient with systemic envenomation complications, and mortality from Russell’s 
viper toxaemia has been noted. (71) This route of administration is likely to have 
value in a field setting prior to transfer to better facilities. 
d. Timing : 
There is no consensus as to the outer limit of time of administration of 
antivenom. Best effects are observed within four hours of bite. (16) It has been noted 
to be effective in symptomatic patients even 6-7 days after the bite. (72) This is 
corroborated by Saini’s observations also.(73) 
e. Response : 
Response to infusion of antivenom is often dramatic (16) with comatose 
patients sitting up and talking coherently with in minutes of administration. 
Normalization of blood pressure is another early response. (70) Within 15 to 30 
minutes bleeding stops though coagulation disturbances may take upto 6 hours to 
normalize. If response to antivenom is not satisfactory use of additional doses is 
advocated. Normalization of clotting time has been taken as end point for therapy (In 
experimental settings) Infusion may be discontinued when satisfactory clinical 
improvement occur even if recommended dose have not been completed. (21) 
f. Reactions : 
i) Early (analphylactic) reaction :  Hypersensitivity reactions including the full 
range of anaphylactic reactions may occur in 3-4 % of cases.  Usually within 10 to 
180 min after starting infusion.  It begins with cough, urticaria, tachycardia, 
palpitations, nausea, vomiting, headache, and fever.  The full blown anaphylactic 
reaction is characterized by hypotension, bronchospasm and angioedema.  These 
usually respond to conventional management including adrenaline, anti histamines 
and corticosteroids. (17) 
ii) Pyrogenic reaction :  It is due to contamination of the antivenin by endotoxin like 
compounds.  It is characterized by chills, goose fleshing, shivering, rise in 
temperature, sweating, vomiting and diarrhoea.  Develops in 1 to 2 hours of 
beginning of therapy.  Treatment involves fanning, tepid sponging, and 
antipyretics. 
iii) Late (serum sickness) reaction :  Develops 5 – 24 (mean 7) days after treatment.  
The symptoms include fever, itching, urticaria, arthralgia, lymphadenopathy, 
periarticular swelling, mononeuritis multiplex, albuminuria and rarely, 
encephalopathy.  It usually responds to antihistamines and corticosteroids. 
g. Availability: 
 In India, polyvalent antivenom is commonly available which is effective 
against the “Big Four”. It can be procured from Central Research Institute, Kasauli 
or Serum Institute of India, Pune.  Antivenom produced at the Haffkine Corporation, 
Parel, Mumbai includes other species as well.  It is however, much more expensive.  
The WHO has designated the Liver pool school of Tropical Medicine as the 
International collaborating centre for antivenom production or testing. 
h. contraindications : 
 There are no absolute contraindications to antivenom in life threatening case 
of snakebite. Caution may be exercised in atopic and previously sensitized 
individuals. 
3.Supportive Therapy  
 Clean the bite site with povidone - iodine, but do not apply dressings. Leave 
blisters alone.  They will break spontaneously and heal.  Alternatively, they can be 
aspirated to dryness with a fine sterile needle. 
 
 
a. Intra compartmental syndrome : 
 This results from swelling of muscles within tight fascial compartments. It 
manifests as severe pain, weakness of compartmental muscles, resistance to passive 
stretching, hyperaesthesia of area of skin supplied by local nerves, and tenseness of 
the compartment.  An intracompartmental pressure of more than 45mm Hg (60 cm of 
H2O) indicates risk of imminent necrosis.  It is a strong indication for fasciotomy to 
relieve the pressure, but such a procedure must be embarked upon only after blood 
coagulability has been restored. 
 If coagulation abnormalities are not corrected by antivenom therapy, it may 
be necessary to administer fresh whole blood, fresh frozen plasma, cryoprecipitate or 
platelet concentrates. (Use of FFP and Fibrinogen are not recommended by some) 
Heparin and epsilon aminocaproic acid have not been found to be beneficial. 
b. Hypotensive Shock : 
 Volume expanders including plasma and blood are recommended, but not 
crystalloids. (16) Persistent shock may require inotrope support under CVP 
monitoring (16). 
c. Renal failure : 
 If urine output falls below 400 ml / 24 hours, insert urinary catheter and 
central venous catheter. If urine flow fails to improve after rehydration, diuretics 
(Frusemide upto 100 mg iv / mannitol) and dopamine (2.5ug / kg / min) should be 
given and patient placed on strict fluid balance. Established renal failure will have to 
be managed by dialysis. Routine antibiotic therapy is not must, (28) though most 
Indian authors recommend use of broadspectum antibiotics (16) 
d. Snake venom opthalmia :    
The spat venom washed from eye, topical anti microbial agent and closure of 
eye with dressing pad with 0.1% adrenaline eye drops relieves the pain. 
           Four cases of tetanus have been documented following snakebite, (27) hence 
tetanus toxoid is a must. Early surgical debridement is generally beneficial, (16, 70) 
though fasciotomy is usually more harmful than useful. (16, 70) There is no role for 
steroid therapy in acute snakebite. (27) Although it delays the appearance of 
necrosis, it does not lessen the severity of outcome (29). 
          Recent studies have reported the beneficial effects of intravenous 
immunoglobulin (IvIg) in ophitoxaemia.  There are suggestions that its 
administration may improve coagulopathy, and eliminates the need to repeat 
antivenom for envenomation associated with coagulopathy. (76) A compound 
extracted from the Indian Medicinal plant Hemidesmus indicus R (2-hydroxy 4- 
methoxy benzoic acid) (77) has been noted to have potent anti-inflammatory, 
antipyretic and antioxidant properties particularly against Russell’s viper venom 
(78). 
Postmortem appearances  
 In India, a significant proportion of mediolegal autopsies comprise cases of 
alleged snakebite.  Unfortunatelly, some of these are cover-ups for death caused by 
foulplay. (Poisoning, mechanical asphyxia, etc)  Since physical signs of 
envenomation need not be present even in a case of genuine snakebite and chemical 
analysis frequently reveals nothing, the doctor doing autopsy in a case of alleged 
snakebite must always exercise great caution while giving an opinion.  A careful 
search must always be made from head to toe for evidence of fang marks. In case 
this is located, the skin and underlying tissues to a depth of a few centimeters must 
be cutout and submitted for analysis.  In unequivocal cases there may be clearcut 
evidence of envenomation, the post mortem signs depending mainly on the nature of 
the snake. 
Mediolegal Importance  
The vast majority of snakebites are accidental in nature. Homicide may rarely 
be committed, for instance by throwing a venomous snake on a sleeping victim or 
slipping it under the bathroom door. Suicides are virtually unreported (with the 
famous exception of Queen Cleopatra who is reputed to have committed suicide by 
having a venomous snake, an asp bite her). Some times snake venom is used to kill 
cattle. 
Prevention  
 The snakebite can be avoided by, carrying torch while walking in snake- 
infested areas. Wearing boots, shocks, and long trousers while working in field. 
Using a stick, which if tapped on the ground scares away the most of the snakes. 
Snakes never be disturbed or attacked or handled. The snake should not be 
indiscriminately destroyed since; they play a major role in keeping the rodent 
population under cheek.  Potent antivenom in sufficient quantity should be ready in 
all hospital in snake- infested areas. 
Capillary Leak Syndrome(105)    
It is characterized by hypotension with haemoconcentration, 
hypoalbuminemia without albuminuria and generalized edema due to increased 
capillary permeability. Inflammatory mediators play a key role in CLS. The Etiology 
of which is multiple, starting from snakebite and dengue fever to sepsis and drugs. 
Typically the syndrome manifests in two phases: Initial capillary leak phase 
characterized by generalized edema, serous effusion and hypotension, which is 
followed by phase of volume overload or Recruitment phase. 
Treatment :  
 It is in the form of fluid replacement to vasopressor therapy and inotropic 
support during capillary leak phase. Diuretics during volume overload phase. 
Specific treatment, in the form of ASV. Prognosis however is poor in most of the 
patients. Disease modifying agents like Theophylline, Terbutaline, Leucotrine 
inhibitors – Monteleukast, Zafarleukast have been shown to terminate an acute 
episode. 
 Plasmapheresis, steroids, prostacyclin have been tried in individual patients 
with variable success. Endothelial cell apoptosis has been shown to be increased in 
CLS and apoptosis is induced by reactive oxygen species (ROS). Studies have 
shown that antioxidants protect against endothelial cell apoptosis. Endothelium 
stabilizing agents may have a role in treatment. 
Disseminated Intravascular coagulation (98) 
 It is characterized by Thrombo-haemorrhagic disorder, which includes a wide 
spectrum of coagulopathy ranging from subclinical bleeding diathesis to the most 
fulminant haemorrhagic emergencies.  The basic pathology is wide spread 
thrombotic occlusion of many small vessels, lead to multiorgan failure, due to 
ischaemic necrosis. 
Etiology : 
 It occurs in varied condition like gram (-ve) septicemia, malaria, and various 
obsteritical problems, following trauma, leukaemia, and snakebite, anaphylaxis and 
incompaitable blood transfusion. 
Pathogenesis :  It starts with (1) Damage to endothelium with activation of 
intrinsic pathway of coagulant cascade or, (2)Release of thromboplastin like 
materials from tissue with activation of extrinsic pathway or,(3)The injection of 
procoagulant of various snake venom -Russell’s viper, saw – scaled viper, pit 
viper.In Viper bite two major procoagulant activate factor X and V. 
These potent thrombogenic stimuli cause the deposition of small thrombi and 
emboli throughout microvasculature. This early thrombotic phase of DIC is then 
followed by a phase of procoagulant consumption and secondary fibrinolysis, 
deposition of fibrin in the kidney and other organs. With severe systemic 
envenomation there are wide spread spontaneous haemorrhage resulting from the 
coagulation factor and platelet depletion and the antihaemostatic effects of fibrin 
degradation products. 
Clinical Features : 
The clinical presentation varies with the stage and severity of the syndrome. 
Most patients have extensive skin and mucous membrane bleeding and haemorrhage 
from surgical incisions or venipuncture or catheter sites. Less often, patients may 
present with peripheral acrocyanosis, thrombosis, and pregangrenous changes in 
digits, genitalia and nose areas where blood flow is markedly reduced by vasospasm 
or microthrombi. 
Cause of Death includes 
Early shock from haemorrhage, vasodilatation and increased capillary 
permeability, intracerebral and subarachnoid haemorrhage, late shock from massive 
gastro intestinal haemorrhage, pituitary adrenal insufficiency following haemorrhage 
or infarction, and acute renal failure 
Diagnosis : 
 The diagnosis is by clinical features and laboratory investigations.  In DIC, 
the time of test is vital, since the pattern of abnormality is continuosly changing.  
Hence, sequential testing is necessary to judge improvement or deterioration over the 
period of time. The laboratory manifestations include, thrombocytopenia, and the 
presence of schistocytes or fragmented RBC’s that arise from cell trapping and 
damage with in fibrin thrombi; prolonged PT and aPTT and thrombin time and a 
reduced fibrinogen level and elevated fibrin degradation products (FDP) from 
intense secondary fibrinolysis.  The D – Dimer immuno assay, which measures cross 
– linked fibrin derivatives, is a more specific FDP assay.  The simple test of whole 
blood clotting time  > 20 minutes indicate coagulation abnormality. 
Treatment : 
 DIC, although sometimes indolent, can cause life threatening haemorrhage 
and may require emergency treatment including correction of the underlying cause 
(with ASV), controlling the major symptom, either bleeding or thrombosis. Patients 
with bleeding should receive fresh frozen plasma to replace depleted clotting factors 
and platelet concentrates to correct thrombocytopenia. Those with acrocyanosis and 
incipient gangrene or other thrombotic problems need immediate anticoagulation 
with intravenous heparin.  The use of heparin in the treatment of bleeding is still 
controversial.  Although it is a logical way to reduce thrombosis formation and 
prevent further consumption of clotting proteins, it should be reserved for patients 
with thrombosis or who continue to bleed despite vigorous treatment with plasma 
and platelets.  So, the use of heparin should be weighed against risk of bleeding and 
hence caution is advocated. (1) 
Antithrombin III :  It’s role is to neutralize excessively generated thrombin. The 
dose is 120-250 units / kg / day for 2-3 days. Clemens et al documented 
complementary effects between antivenom and AT III in controlling of both 
fibrinopeptide A (FPA) and platelet Factor 4 (PF-4) release induced by the venom. 
Further more, in this invitro experiment, AT III alone (high dose) when administered 
in a sufficient dose abolished the procoagulant effects of Russell’s viper venom. (58) 
The human activated protein C (APC) helps in amelioration of haemorrhage 
of DIC, more effective and cause less bleeding than heparin. The drug under trial are 
Dx 9065 A novel, synthetic, selective and orally active inhibitor of Factor X a. 
Apoprotein can be used for hyper fibrinogenolysis. The DIC is the 
complication of haemotoxic snake envenomation.  It is then responsible for many of 
the complication of snakebite such as renal failure, ICH, and hypotension and 
important cause of death among snake envenomation and it should be attempted 
promptly. 
ACUTE RENAL FAILURE 
Definition :     Acute renal failure is a sudden decrease in the glomerular filtration 
rate (GFR) occuring over a period of hours to days and resulting in the failure of the 
kidney to excrete nitrogenous waste products and maintain fluid and electrolyte 
homeostasis. 
Recognition of acute renal failure : 
 Clinically, ARF is recognized by an increase in serum creatinine and blood 
urea nitrogen.  Practically and in clinical trials of ARF, an increase in creatinine of 
50% above baseline or an increase of 0.5 mg per dl are commonly used definitions of 
ARF.ARF may occur in patients with previously normal renal function or patients 
with chronic kidney disease (CKD); in either case, the clinical approach to find and 
treat the cause remain similar. 
 ARF is typically described as either oliguric or nonoliguric. Oliguria is 
defined as a urine output of less than 400 ml per day.  400 ml is the minimum 
amount of urine that a person in a normal metabolic state must excrete to get rid of 
the daily solute production. ARF is usually asymptomatic and diagnosed when 
biochemical monitoring of hospitalized patients reveals a recent increase in blood 
urea and creatinine concentrations. Oliguria is a frequent but not invariable clinical 
feature.  Most ARF are reversible. 
Classification of ARF : 
Prerenal ARF: (55%) diseases that cause renal hypoperfusion without 
compromising the integrity of renal parenchyma. Intrinsic renal ARF: (40%) 
diseases that directly involve renal parenchyma. Post renal ARF: (5%), diseases 
associated with urinary tract obstruction. 
ARF in Snake envenomation (94) 
 ARF is mainly observed following bites by the viperidae group, sea snakes, 
and the colubridae group, but substantial proportion of these cases do result from 
viper bites. 
 In India, particularly in the Ratnagiri district of Maharashtra, Punjab, 
Kashmir, Sandy deserts of Rajesthan and west coast upto Karwar, Echis carinatus or 
Saw Scaled Viper are found in incredible numbers. The incidence of ARF following 
poisonous snakebite varies from 13-22% following Echis carinatus or Russell’s viper 
bite. (Mitral B.V. et al 1994)(8) According to chugh K.S. et al 1989. ARF incidence 
is 5% - 30%. (86) It may develop within hours to 4 days of the envenomation. A 
history of oliguria or anuria, loin pain and 50% of patients with history of cola 
coloured urine is commonly seen.  In 6% of cases nonoliguric renal failure is seen.  
Pathology : 
 On gross examination, the kidney size may be normal, or enlarged and the 
surface may show petechial haemorrhages.  Light microscopy shows acute tubular 
necrosis in 70 to 80% of patients (chugh 1989). (86) Electron microscopy reveals 
dense intracytoplasmic bodies representing degenerated organlles in the proximal 
tubules. 
Acute cortical necrosis carries the worst prognosis and is seen in about 20 to 25% 
of cases (Chugh et al 1984). (43) 
Other lesions, which have been described in these patients, include 
 Acute interstitial nephritis with prolonged oliguria (Sit Prija et al 1982)(26); 
which may result from a hypersensitivity reaction to some component of the snake 
venom. (Gundappa RK et al 2002)(84) Ballooning of glomerular capillaries, 
thickening and splitting of glomerular basement membrane, (Acharya V.N 1989) 
(Merchant MR 1989)(38)(52) swelling of endothelial cells, focal proliferation of 
measangial cells, tubular degeneration and glomerular changes, (Merchant MR, 
1989). (52) Necrotizing vasculitis and nephrotic syndrome have also been reported. 
(Mittal B.V. 1994)(8) Occassionally, crescentric glomenulonephritis has been 
reported. (Seedat et al 1974, Sitprija et al 1982) Deposition of IgM and C3 in 
glomerular measangium with extension along the capillary walls, dense deposits of 
C3 in the arteriolar walls were noted in viperbite and cobra bite. (Sit prija .V)(92) 
Pathogenesis : 
 A number of clinical and experimental studies have provided insights into the 
pathogenic mechanisms that lead to acute renal failure in snake envenomation 
patients. 
  Haemodynamic alterations induced by cytokines and vasoactive mediators 
leading to renal ischaemia are important in the pathogenesis of ARF. (Sitprija V et 
al)(85) Intravascular haemolysis and rhabdomyolysis are important contributing 
factors. (43)  Metalloproteases and phospholipase A2 can induce direct 
nephrotoxicity. (31,107) Immunological mechanism plays a minor role in the 
pathogenic of renal lesion. (92) 
1.Hypotension and circulatory collapse :It is resulting from massive bleeding 
(DIC), increased vascular permeability, release of kinins, and depression of the 
medullary vasomotor centre and myocardial depression.  Hypotension and shock 
play a significant pathogenetic role in the causation of acute tubular necrosis. 
(Minton 1971)  Kinin-forming enzymes (kininogenases) are present in crotalid 
venom. (Mebs 1970). Vipera palastinae venom is thought to cause shock by 
depression of medullary vasomotor centre.  Bitis ariefans venom causes hypotension 
through a combination of myocardial depression, arteriolar dilatation, and increased 
vascular permeability. 
2.Intravascular Haemolysis : 
  The haemolysis results from the action of phospholipase A2 and a basic 
protein called ‘direct lytic factor’. Phospholipase A2 present in venom of most of the 
snakes acts on plasma lecithin, leading to the production of haemolytic lysolecithin. 
(Condrea et al 1964, Chugh et al 1975) Microangiopathic haemolytic anaemia has 
been recorded following Russell Viper bites (Chugh et al 1975), which may be of 
pathogenetic importance in the development of acute renal failure. 
3.Direct Nephrotoxicity : 
Some investigators have produced evidence that the renal lesions are due to 
the direct cytotoxic effects of the snake venom on the kidney. (Harding and Welch 
1980) The Kidney is particularly vulnerable to the effects of the toxins because of its 
high blood flow rate and capacity to concentrate these substances in the urine. 
Willinger et al 1995 have shown extensive destruction of the glomerular filter, lysis 
of vessel wall, and epithelial cell injury in all segments of the tubule in experiements 
with Russell’s Viper venom. 
A vasculotoxic factor has been isolated from the venoms of several snakes 
including E. Carinatus and viper palastinae. Win Aung et al 1998 described direct 
toxic effect of Russell’s Viper venom on the kidney in the absence of DIC.However 
the occurrence of these lesions has not been confirmed by all workers. 
4.Disseminated intravascular coagulation : 
One of the important findings observed in experimental animals as well as in 
patients bitten by Viper snakes is DIC.The Viper venom activates the coagulation 
cascade at a number of sites, leading to rapid thrombin formation. The presence of 
fibrin thrombi in the renal microvasculature in the histological specimens both in 
clinical and experimental studies points to the role of DIC in the genesis of renal 
lesions. (Chugh et al 1975, 1984) 
Complications of Acute renal failure : 
ARF impairs renal excretion of sodium, potassium and water and perturbs 
divalent cation homeostasis and urinary acidification mechanism.  As a result, ARF 
is frequently complicated by intravascular volume overload, hyponatremia, 
hyperkalemia, hyperphosphatemia, hypocalcemia, hypermagnesemia, and metabolic 
acidosis. In addition, patients are unable to excrete nitrogenous waste products and 
are prone to develop the uraemic syndrome. 
Expansion of extracellular fluid volume is an inevitable consequence of 
diminished salt and water excretion in oliguric or anuric individuals. Whereas milder 
forms are characterized by weight gain, bibasilar lung crackles, raised JVP, and 
dependent edema, continued volume expansion may precipitate life threatening 
pulmonary edema.  
Hyperkalemia is a frequent complication of ARF, due to impaired excretion 
of ingested or infused potassium, and potassium releaed from injured tissues 
(hemolysis, rhabdomyolysis and tumor lysis syndromes). Coexistent metabolic 
acidosis may exacerbate hyperkalemia by promoting potassium efflux from cells. 
Mild hyperkalemia (< 6 mmol / L) is usually asymptomatic, Higher levels may 
trigger ECG abnormalities or arrythmias. 
ARF is typically complicated by metabolic acidosis since; metabolism of 
dietary proteins yields 50 and 100 mmol/d of fixed nonvolatile acids that are 
normally excreted by the kidneys. Mild hyperphosphatemia is an almost invariable 
complication of ARF.  Severe hyperphosphatemia may develop in highly catabolic 
patients or following rhabdomyolysis, hemolyis, or tumour lysis.  Hypocalcemia due 
to tissue resistance to the action of parathyroid hormone, and reduced levels of 1,25 
dihydroxy vitamin D. Hypocalcemia is often asymptomatic but can cause perioral 
paresthesia, muscle cramps, seizures, hallucination, confusion, prolongation of QT 
interval and nonspecific T wave changes on ECG. 
Anaemia develops rapidly in ARF and is usually mild and multi factorial in 
origin. Contributing factors include impaired erythropoiesis, hemolysis, bleeding, 
hemodilution, and reduced red cell survival time. Prolongation of bleeding time and 
leucocytosis are also common.  Common contributors to the bleeding diasthesis 
include the thrombocytopenia (mild), platelet dysfunction, or clotting factor 
abnormalities. (Factor VII dysfunction) Leucocytosis usually reflects sepsis, a stress 
response.  
Infection is a common and serious complication of ARF; occurring in 50 to 
90% of cases and accounting for up to 75% deaths.  It is unclear whether patients 
with ARF have a clinically significant defect in host immune responses or breaches 
of mucocutaneous barriers. 
Cardio pulmonary complications of ARF include arrythmias, myocardial 
infarction, pericarditis, and pericardial effusion, pulmonary edema, and pulmonary 
embolism. Mild gastro intestinal bleeding is common (10 to 30%) and is due to 
stress ulceration of gastric or small intestinal mucosa. 
Vigorous diuresis during the recovery phase of ARF, which may on 
occasions, be inappropriate and lead to intravascular volume depeletion and 
secondary prerenal ARF, Hypernatremia, less commonly hypokalemia, 
hypomagnesemia, hypophosphatemia, and hypocalcemia. 
Management of ARF in snakebite : 
 The therapeutic approach to renal failure following snakebite is the same that 
for ARF of any other cause.  The additional problem like bleeding, shock, and sepsis 
are threat to patient life should be attended promptly.  In addition to serotherapy with 
ASV the following measure should be done. 
Fluid and Electrolytes Management : 
1) Intravascular volume over load : Salt (1-2 g / day) and water (1L/d) restriction, 
diuretics (usually loop blockers + thiazide) and ultra filtration or dialysis. 
2)  Hyponatremia :Restriction of enteral free water intake (<1 L/d).  Avoid 
hypotonic intravenous solution including dextrose. 
3) Hyperkalemia : Restriction of dietary K+ intake (< 40 mmol / day),eliminate K+ 
supplements and K+ sparing diuretics,intake of  potassium binding ion exchange 
resins (sodium polystyrene sulphonate),glucose (50 ml of 50% Dextrose) and Insulin 
( 10 units regular),sodium bicarbonate (50-100 mmol),calcium gluconate (10 ml of 
10% solution over 5 minutes),and dialysis with low K+ dialysate. 
4) Metabolic acidosis : Restriction of dietary proteins (0.6 g / kg / day of high 
biologic value),or use of sodium bicarbonate (maintain serum HCO3 > 15 mmol / L 
or arterial pH > 7.2) and dialysis. 
5) Hyperphosphatemia : Restriction of dietary phosphate intake (<800 mg / day) 
and intake of Phosphate binding agents. (Calcium carbonate, aluminium hydroxide) 
6) Hypocalcemia : Treated with Calcium carbonate (if symptomatic or if sodium 
bicarbonate to be administered), Calcium gluconate. (10 – 20 ml of 10% solution) 
7) Nutrition : Restriction of dietary protein (0.6 g / kg / day), carbohydrate (100 g / 
day), enteral or parenteral nutrition .(if recovery prolonged or patient very catabolic) 
8)Indication for dialysis : Clinical evidence (symptoms or signs) of uremia, 
intractable intravascular volume overload, hyperkalemia or severe acidosis resistant 
to conservative measures?  Prophylactic dialysis when urea > 100 – 150 mg / dl, or 
creatinine > 8-10 mg / dl. 
Severe hyperkalemia may be present in the course of renal failure in patients 
with intravascular haemolysis and may necessitate immediate dialysis. With 
effective management, oliguria resolves in 2-3 weeks but may be persist in patients 
with acute cortical necrosis. Early administration of ASV prevents renal damage 
however severe the coagulation abnormality (Vijeth. S.R. et al 1997). (107) In 
contrast, according to Chen J.B. et al 1997, (36) early administration of ASV cannot 
be too strongly emphasized to prevent development of ARF. 
 
Newer agents under trial includes :  Natriuretic peptides – in oliguric renal failure, 
omega –3 fathyacids,adhesin molecule,growth factor – Epidermal growth factor, 
hepatocyte growth factor and insulin growth factor – reduce the extent of renal 
dysfunction and accelerate the recovery of kidneys,replacement therapy in addition 
to hemodialysis, peritoneal dialysis, continous veno venous hemofiltration, 
continuous arterio venous hemofiltration may be advocated. 
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Outcome and long term prognosis of ARF : 
The mortality rate among patients with ARF approximates 50% and has 
changed little over the past 30 years, vary greatly depending on the cause of 
ARF.Oliguria at time of presentation and a rise in serum creatinine of > 3 mg / dl are 
associated with a poor prognosis and probably reflect the severity of renal injury and 
of the primary illness. Mortality rates are higher in older debilitated patients and in 
those with multiorgan failure. Most patients who survive an episode of ARF recover 
sufficient renal function to live normal lives.  However, 50% have subclinical 
impairment of renal function or residual scarring on renal biopsy. Approximately 5% 
of patients never recover function and require long- term renal replacement with 
dialysis or transplantation. 
MATERIALS AND METHODOLOGY 
All patients admitted to the medial wards of Government Rajaji Hospital, with 
history of snakebite from July 2006 to June 2007 were included in this study. The 
study was a prospective one. The patients of both sexes of all age group excluding 
the paediatric group were included in this study. 
Inclusion Criteria : 
i) Patients with history of snake bite with cellulitis either with bleeding 
diathesis or with prolonged clotting time or both.  
ii) Patients with history of snake bite with oliguria irrespective of the number 
of days since time of bite. 
 
 
Exclusion Criteria : 
i) Patients with history of snakebite with any neurological problems such as 
ptosis, respiratory failure etc. 
ii) Patient without bite mark. 
A detailed history was recorded from all patients, with special emphasis on 
the following points, 1.Snakebite in relation to time of bite, number and site of bite, 
whether tourniquet applied or not. 2.Any bleeding diathesis including bleeding from 
the bitten area/ bleeding gums/ haematamesis/ Malena/ haemoptysis/ haematuria/ 
epitaxis and their time of onset. 3.Pre existing illness if any, mainly history in 
relation to severe anaemia. 4.History in relation to urine output, colour of the urine, 
and the time of onset of oliguria or anuria if any, since time of bite.  
 
 
Examination of the patients with special reference to : 
1. Site of the bite, look for bite mark, any local incision, bleb, blisters, skin 
necrosis, sloughing and gangrene if any, and regional adenitis and cellulitis.     2. 
Vital signs – pulse, blood pressure, temperature, respiratory rate and the level of 
consciousness. 3.Look for anaemia, jaundice, pedal edema, priorbital edema and 
stigmata of renal failure. 
 
Investigations : 
 Urine analysis for albumin, sugar, RBC’s deposits, bilesalts, bile pigments. 
Blood – TC, DC, ESR, Hb%, bleeding time, clotting time, peripheral smear for 
fragmented RBC’s, platelet counts, fibrinogen and reticulocyte count. Blood urea, 
creatinine and electrolytes. ECG, USG abdomen, CT brain whenever needed. The 
investigations were done on the day of admission and whenever needed. 
 
Management aspects : Focus on the following : 
1.Onset of treatment since bite. 2.Total number of vials of antivenom used. 
3.The supportive therapy for acute renal failure such as lasix, dopamine and its dose 
and days. 4.Avoidance of nephrotoxic drugs. 5.Blood transfusion and treatment for 
circulatory failure and hypotension. 6.Peritoneal and haemodialysis, number of 
cycles and days. 7.Outcome of medical management. 8.Any other complications 
noted other than renal failure.  9.If the outcome was fatal – time of death since time 
of bite, if possible trace out the probable cause of death. 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL OBSERVATION 
 This study was conducted on 107 patients admitted to medical wards of 
Madurai Government Rajaji Hospital during the period from July 2006 to June 
2007.The study was a prospective one.  Both male and female cases were taken for 
the study. 
1.Renal failure – Incidence  : 
 
Totalno.of cases Renal failure Percentage 
        107            25        23.4 
 
 Incidence of renal failure 25/107 - 23.4% 
 Oliguric renal failure 20/25  - 80% 
 Non oliguric renal failure 5/25  - 20% 
2.Sex Distribution : 
 A total of 107 cases were taken for study of which 75 cases were male and the 
remaining 32 were female. 
i)  Total Distribution : 
Sex No.of patients Percentage 
Male 75 70.1  
Female 32 29.9  
Total 107 100  
 
 
ii)  Sex – Renal failure :   
Renal failure          Sex Total no of 
patients No.of patients Percentage 
Male 75 17 22.66 
Female 32 8 25 
Total 107 25 23.4 
 
iii)   Sex – Death :      
Death Sex Total no of 
patients No.of patients Percentage 
Male 75 3 4 
Female 32 0 - 
Total 107 3 2.8 
 
 The data shows that most of the snakebite victims were males. 
 The renal failure incidence 
  Total  25/107 - 23.4% 
  Male 17/75  - 22.66% 
  Female  8/32   - 25% 
 The Death Incidence  
  Total 3/107  - 2.8% 
  Male   3/75  - 4% 
  Female    -           0 
 
3.Age Distribution : 
i)Total Distribution     
Male Female Total Age (yrs) 
Enveno 
mation 
% Enveno 
mation 
% Total % 
14-30 35 46.7 18 56.3 53 49.5 
31-40 14 18.7 4 12.5 18 16.9 
41-50 11 14.7 4 12.5 15 14.0 
51-60 11 14.7 6 18.7 17 15.9 
> 60 4 5.2 0 - 4 3.7 
Total 75 100 32 100 107 100 
 
ii)Age – Renal Failure : 
Male Female Total  
Age(yrs) Enveno 
mation 
Renal 
failure 
% Enveno 
mation 
Renal 
failure 
% Enveno 
mation 
Renal 
failure 
% 
14-30 35 9 25.7 18 3 16.7 53 12 22.6 
31-40 14 2 14.3 4 1 25 18 3 16.7 
41-50 11 2 18.2 4 1 25 15 3 20 
51-60 11 2 18.2 6 3 50 17 5 29.4 
> 60 4 2 50 - - - 4 2 50 
Total 75 17 22.7 32 8 25 107 25 23.4 
 
 
 
iii)  Age - Death 
Male Female  
Age (yrs) Enveno 
mation 
Death % Enveno 
mation 
Death % 
14-30 35 2 5.7 18 - - 
31-40 14 1 7.1 4 - - 
41-50 11 - - 4 - - 
51-60 11 - - 6 - - 
> 60 4 - - - - - 
Total 75 3 4 32 - - 
 
 Age of study group ranged between 14-70 years 
  49.5% of them were below 30 years 
  80.4% of them were below 50 years 
  19.6% of them were above 50 years 
  Incidence of renal failure : 
 14-30 years of age 12/53 - 22.6% 
 14 – 50 yrs of age 18/86 - 20.9% 
 > 60 yrs of age   2/4  - 50% 
 
 
 
 
 
4.Site of Bite : 
Site of Bite No.of cases Percentage 
Lower limb 88 82.25 
Upper limb 18 16.82 
Back 1 0.93 
Total 107 100 
 
5.Tourniquet Distribution : 
 No.of cases treated with tourniquet    -    67/107 - 66.62% 
 No.of cases not treated with tourniquet             -   40/107 - 37.38% 
Envenomation Renal failure Death  Tourniquet 
Total % Total % Total % 
Yes 67 66.62 16 23.9 1 1.5 
No 40 37.38 9 22.5 2 5 
Total 107 100 25 23.4 3 2.8 
 
 The Renal failure Incidence : 
  Tourniquet group  - 16/67   - 23.9%  
  Non -tourniquet group - 9/40  - 22.5%  
 The Death Incidence : 
  Tourniquet group  - 1/67  - 1.5% 
  Non -tourniquet group - 2/40  - 5% 
 
6.Bleeding diathesis – Distribution : 
 Total number of cases presented with bleeding diathesis    - 31 cases 
i)  Bleeding diathesis Incidence - 31/107 - 28.97% 
Time interval since 
bite (hrs) 
No.of cases Percentage 
0-2 10 32.26 
3-6 11 35.48 
7-24 9 29.03 
25-48 1 3.23 
Total 31 100 
 
ii) Time interval since bite  (hrs) 
  0 – 6  - 21 cases - 67.74 % 
  0 – 24            - 30 cases - 96.77 % 
  25-48  - 1 case            - 3.23% 
iii) Type of bleeding – Distribution  (31/107) 
Type No.of cases Percentage 
Bleeding gums 14 45.16 
Haematuria 2 06.45 
Haematamesis 4 12.90 
Haemoptysis 1 3.23 
Malena 2 6.45 
Multiple sites 8 25.81 
Total 31 100 
7.Bleeding diathesis and Renal failure : 
 Bleeding diathesis Renal failure 
 No.of cases Total cases % 
Yes 31 16 51.61 
No 76 9 11.84 
Total 107 25 23.4 
  
Bleeding diathesis with renal failure                   -  16/31 -  51.61% 
 Bleeding diathesis without renal failure               - 15/31   - 48.39 % 
 Prolonged clotting time and bleeding diathesis      - 27/31         -  87.1% 
 Normal clotting time and bleeding diathesis    -  4/31          - 12.9% 
 
8.Clotting time distribution : 
 No.of cases with prolonged clotting time -   101/107   - 94.39% 
 No.of cases with normal clotting time -   6/107           -        5.61 % 
i)  Clotting time and Renal failure : 
 Renal failure 
CT No.of cases No.of cases % 
Prolonged 101 21 20.8 
Normal 6 4 66.7 
Total 107 25 23.4 
 
 Prolonged CT with renal failure - 21 / 101 -  20.79% 
 Normal CT with renal failure - 4 / 6   - 66.66% 
ii) Number of ASV vials required for normalization of clotting time 
  Range Æ 4- 25 vials 
  Mean Æ        13 vials 
9.Distribution of onset of treatment  (ASV) and Renal failure : 
Envenomation Renal failure Time of onset of 
Treatment (hrs) No.of cases % No.of cases % 
1 – 12 89 83.18 18 20.2 
13 – 24 12 11.21 2 16.7 
25 – 48 4 3.74 3 75 
> 48 2 1.87 2 100 
Total 107 100 25 23.4 
 
Renal failure Incidence : 
 Onset of treatment (ASV)  (1-24 hrs)   - 20/101 - 36.9% 
 Onset of treatment (25-48 hrs)        - 3 / 4  - 75% 
 Onset of treatment  >  48 hrs        -   2 / 2  - 100%  
10.Distribution of Relationship between preexisting anaemia and Renal failure  
Envenomation Renal failure Anaemia 
No.of cases % No.of cases % 
Yes 11 10.28 10 90.91 
No 96 89.72 15 15.63 
Total 107 100 25 23.4 
 
 
Renal failure Incidence : 
 Patients with pre existing anaemia - 10/11    - 90.91 % 
 Patients without preexisting anaemia- 15/96    -       15.63% 
11.Distribution of time of onset of renal failure : 
Time (hrs) No.of cases Percentage 
<  12 5 20 
13 – 24 11 44 
25 – 36 4 16 
37 – 48 3 12 
> 48 2 8 
Total 25 100 
 
 Time of onset of renal failure   
  Range    - (1 ½ hrs-56 hrs) 
  Mean     -  25hrs 
 Renal failure incidence  
  Within 24 hrs  -16 cases -16/25    -  64% 
  After 24 hrs     - 9 cases -9 / 25    -  36% 
 
 
 
 
 
12.Distribution of probable etiology of renal failure : 
S.No. Probable etiology No.of cases % 
1. DIC 12 48 
2. DIC with hypotension 4 16 
3. DIC with shock and capillary 
leak syndrome 
2 8 
4. DIC with shock and sepsis 1 4 
5. Direct nephrotoxicity 6 24 
 Total 25 100 
 
13.Distribution of management of renal Failure : 
    Outcome    No.of renal 
failure cases 
Supportive treatment 
Improved Not improved 
25 25 14(56%) 11(44%) 
 
Outcome of supportive therapy for renal failure : 
 Total no.of renal failure cases   - 25 
 All 25 cases treated with supportive therapy 
 Outcome : Improved - 14/25    - 56% 
   Not improved- 11/25    - 44% 
 Total no.of cases not improved with supportive treatment – 11 cases 
 No.of cases treated with hemodialysis   - 7 cases 
 No.of cases treated with peritoneal dialysis- 4 cases 
 
14.Outcome of hemodialysis : 
 Total No.of cases Improved Not improved 
7 5 (71.43%) 2 (28.57%) 
 
 Total No.of cases treated with hemodialysis   - 7 cases 
  Improved  - 5/7 - 71.43% 
  Notimproved  - 2/7 - 28.57% 
 Total no.of cycles  (Hemodialysis)  
  Range    - 2 – 12 
  Mean    -      6 cycles 
 
15.Outcome of peritoneal dialysis : 
Total No.of cases Improved Not improved 
4 - 4 (100%) 
 
 Total no.of cases treated with peritoneal dialysis  -  4 cases 
  Improved     - Nil 
  Not improved    - 4/4   -  100% 
 
 
 
 
 
 16.Complications  of Snake envenomation : 
S.No. Complications No.of cases % 
1. ARF 25 23.36 
2. Bleeding diathesis 31 28.97 
3. Anaemia 11 10.28 
4. Hypotension / shock 8 7.48 
5. Compartment syndrome 5 4.67 
6. Gangrene 2 1.87 
7. ICH 1 0.93 
8. Sepsis 1 0.93 
9. Jaundice 1 0.93 
10. Stroke (unusual) 1 0.93 
11. Vitreoushaemorrhage(unusual) 1 0.93 
 
 
 
 
 
 
 
 
 
17.Distribution of death due to envenomation in relation to cause, time, and             
interval since bite   . 
                    The study of 107 cases of snakebite envenomation, death occurred in 3 
cases  -  3/107  -  2.8% .                                                                                                                         
Analysis of death and it`s distribution 
S.No. Cause Death – time 
interval since 
bite (hrs) 
Time interval for 
onset of treatment 
(hrs) 
1. DIC with ICH, ARF 72hrs 4 hrs 
2. DIC, circulatory failure, 
ARF and sepsis 
36hrs 5 hrs 
3. DIC, circulatory failure, 
ARF and capillary leak 
syndrome 
84hrs 3 hrs 
 
Analysis of cause of death in snake envenomation : 
 i) DIC with ICH / ARF                       -          1 case 
 ii) DIC, circulatory failure, ARF and sepsis             -                   1  case 
 iii) DIC, circulatory failure, ARF and capillary leak syndrome – 1case 
Analysis of time interval of death since bite 
  Range        -       36hrs - 84hrs 
  Mean         -       64hrs   
Analysis of time interval for onset of treatment : 
 Range         -    3 – 5 hrs 
 Mean          -     4hrs 
DISCUSSION 
 Of the 107 patients included in this study with haemotoxic snake 
envenomation acute renal failure occurred in 25 patients.  While analysis, multiple 
factors were found responsible for the onset of renal failure. 
Incidence of renal failure  
In this study, it was found to be 23.4% (25/107). The incidence of oliguric 
renal failure was 80% (20/25) and nonoliguric renal failure was 20% (5/25). A study 
in PGI Medical science chandigarh by Dr. Chugh et al 1984 it was 28.6% (45/157), 
1989 it was 5% - 30%. A study in Sardarjang hospital in New Delhi by Banerjee and 
Siddiqui 1976, it was observed 16.9%. The study by Verma et al 1982, Chugh et al 
1984, Mather and Raja Rathinam 1987, it was 13-32%. A study from JIPMER by 
Vijeth, Dutta 1997 it was observed 32.5%. A study in Seth G.S. Medical College by 
Mitral B.V. 1994 it was 16.2% and the incidence of oliguric renal failure was 100%. 
So the incidence of renal failure in our hospital in this study was 23.4% and 
when compared to other studies was neither very high nor low. 
Sex and Renal failure  
In this study of 107 cases 70.1 % (75/107) were males and 29.9 % (32/107) 
were females.  Among them the percentage of renal failure was 22.7% (17/75), 25% 
(8/32) respectively.  A study in sardajang hospital (1970-74) showed that 75% were 
male and 25% were female. 
 It was observed from both the studies that males are affected more and was 
mainly attributed to outdoor nature of work. Regarding the incidence of renal failure 
in male and female 22.7 and 25% respectively, there was no obvious reason and 
again information of previous study related to sex is not available. 
Incidence of Death  
In this study, it was observed as 2.8% (3 / 107). In a study from JIPMER by 
Vijeth, 1996, it was noted as 5%. A study from Saudi Arabia by Hisham and Mahaba 
the case fatality rate was 2.9%. According to study by Kulkarni 1981, it was reported 
as 5.2%. According to WHO the global annual mortality of 40,000 of which 10% is 
from India. A study in Chennai Medical College, the death rate was 10% (1989). 
The study of our hospital mortality showed close relation to other previous 
studies.  
Age and renal failure  
 From this study, it was observed that the percentage of envenomation 
decreases with increase in age. ie. Below 30 years it was 49.5% and below 50 years 
it was 80.4% and above 50 years it was 19.6%. The renal failure incidence increase 
with increase in age i.e. age less than 30 years it was 22.6% and age less than 50 
years it was 20.9% whereas in more than 60 years of age it was 50%. 
 The high incidence of renal failure noted in elderly patients, may be attributed 
to anatomical and physiological changes occurring due to ageing process.  The snake 
venom, as it passes through the renal tubules may produce direct nephrotoxic effect. 
Site of Bite  
 From this study it was observed that the most frequent site of bite was the 
lower extremity 82.25% (88/107) and suggests that in most cases the snake is 
inadvertently trodden upon. 
Tourniquet and renal failure  
 The tourniquet is usually applied in order to prevent the spread of venom 
following snakebites.  In this study 67 out of 107 cases (66.62%) used tourniquet as 
a first aid measure. In this evaluation of renal failure in relation to tourniquet are 
23.9% whereas in the cases without tourniquet it was 22.5% and hence, no difference 
between tourniquet group and non-tourniquet group was noted. The death incidence 
in relation to tourniquet, it was observed that the death incidence was more with non-
tourniquet group (5%) when compared with the tourniquet group (1.5%).  
 The study of Amaral CF, Toxicon 1998, in 97 cases stated that there was no 
difference between tourniquet group and non-tourniquet group in the frequency of 
renal failure and other complications, number of deaths and their study stress the 
ineffectiveness of tourniquet.  The above study was controversial to the present 
study. 
 A case report from Department of clinical sciences, University of papua, New 
Guinea showed tourniquet induced ischaemic damage and rhabdomyolysis causing 
acute renal failure and highlights the danger of tourniquet use and sudden release of 
tourniquet. 
 The other consequences of tourniquet are damage to peripheral nerve,  
(Lateral popliteal nerve) increased fibrinolytic activity, congestion, swelling, 
increased bleeding and increased local effect of venom.  (Stewart et al 1981). The 
subsequent release of tourniquet leads to sudden flooding of accumulated venom 
from bitten site to systemic circulation. (Robert Otten et al 1986). 
 Because of the dangers associated, general concensus is against the 
application of tourniquet except in certain conditions like bitten by neurotoxic snakes 
or if medical attention is delayed for 1-2 hrs enroute to hospital (Warrell et al 1996). 
Bleeding diathesis  
 In this study, it was noted that bleeding diathesis rate was 28.97% (31/107).  
It was also noted in this 31 cases, 67.7% of cases bleeding occurred with in 6 hrs and 
96.8% of cases bleeding occurred with in first 24 hrs. The onset of bleeding ranges 
from 30 minutes to 40 hours and so observation for bleeding diathesis is essential 
from the beginning. 
 The common type of bleeding noted according to this study was bleeding 
gums 45.16%.  Next to this, haematamesis 12.9%, haematuria 6.45%, malena 6.45%, 
and haemoptysis 3.23%. The incidence of multiple bleeding sites was 25.81%. 
Haematamesis and bleeding gums were the commonest types of systemic bleeding 
following viperine bite.  (Mahasundanas et al 1980). 
 It was also observed that the Incidence of renal failure in the cases with 
bleeding diathesis was 51.61% (16/31) and cases without bleeding diathesis was 
11.84% (9/76).  According to present study bleeding diathesis secondary to 
disseminated Intra vascular coagulation is enough to produce hypotension and it is 
the important cause of acute renal failure in haemotoxic snake envenomation. 
 A study by Chen JB et al 1997, Factors contributing to acute renal failure 
following viperine bite are haemorrhage, hypotension, DIC, hemolysis and 
Rhabdomyolysis.Intravascular hemolysis and DIC contributed to the development of 
acute Renal failure. (chugh KS et al 1975) DIC is the important cause of renal 
dysfunction in most of the cases of ARF. (Vijeth ST et al 1997). Acute Renal failure 
often associated with haemorrhagic diathesis, intravascular hemolysis and 
Rhabdomyolysis. (Sitprija V et al 2006). 
 The above studies strongly support our present study. 
Clotting Time  
 In our study it was observed that prolonged clotting time was noted in 94.39% 
of cases. (101/107). The incidence of renal failure in the cases with prolonged 
clotting time was 20.8% (21/101) where as, in cases with normal clotting time it was 
66.7% (4/6).  According to present study, the acute renal failure occurred in these 
cases in the absence of DIC, which might be due to direct nephrotoxic action of 
venom. 
   Direct toxicity caused by venom could be responsible for renal dysfunction 
in certain cases.  (Vijeth SR et al 1997) (Win-Aung 1998). Although hypotension, 
hemolysis and DIC are likely to be important pathogenetic factors, a direct 
nephrotoxic effect of the venom on the kidney in producing ARF cannot be 
excluded. (Chugh KS et al 1984). 
 The above studies strongly supports direct nephrotoxic action of venom and 
also supports present study. 
 The study by Bhat 1974 in India, it was observed that 60-270 ml (average of 
12vials) needed to resume the clotting time normal .In the present study, the dose of 
ASV used among envenomation cases for normalization of clotting time was 40 ml – 
250 ml. The mean was 13vials. When compared with Bhat study of ASV 
requirement, not of much difference in the dose utilization. 
Onset of Treatment since Bite  
 ASV should be given with same sense of urgency as one shown while using 
streptokinase in acute infarction. When the onset of treatment with ASV was within 
24 hrs, the incidence of renal failure observed was 36.9% (20/101).  In cases with 
onset of treatment with ASV after 48 hrs, the incidence of renal failure was 100% 
(2/2). So, delay in onset of treatment since bite resulted in renal failure.  In patients 
with early treatment with ASV if renal failure develops, it may be due to either 
severe envenomation or inadequate dose of ASV. 
 The study of renal failure in 40 cases of Viper envenomation by Vijeth ST et 
al, the use of ASV with in 8 hrs, no renal abnormality occurred. The study by 
Narvencar K. et al 2006 stated that early administration of ASV is beneficial in 
preventing complications however severe is the systemic envenomation. 
Pre existing anaemia and renal failure  
 The preexisting anaemia was noted in 11 out of 107 cases.  The study of renal 
failure in cases without anaemia (96/107) was 15.6% and in cases with anaemia 
(11/107) was 90.9%. So the presence of severe anaemia may aggravate the process 
of ongoing renal failure. The renal ischaemia is a consequence of envenomation.  
The presence of anaemia may worsen the hypoxia and persistent hypoxia in outer 
medulla ended in acute tubular necrosis.  (The kidney by Brenner). 
Time of onset of renal failure since bite  
 The present study showed that the range of time of onset of renal failure was 
1 ½ hrs – 56 hrs.  The mean was 25hrs. It occurred with in 24 hrs in 64% of cases 
and after 24 hrs in 36% of cases. The previous study it was found that the renal 
failure occurred within 24 hrs and lasted for 17-26 hrs.  (Chen JB et al 1997) The 
range of time of onset of renal failure according to Sit prija et al 1974 was few hours 
to 96 hours.  According to Chugh et al 1984 it was with in hours to 3 days. 
 The Disseminated intravascular coagulation, the complication of 
envenomation, can occur as early as with in 2 hours.  In DIC there is activation of 
coagulation cascade, which leads to microthrombi in number of sites including renal 
vasculature.  So it is possible for renal failure to occur earlier. (Chugh et al 1984, 
Warrell et al 1977, Sitprija et al 1974) 
Etiology of Renal failure  
 In this study, the etiology of renal failure was multifactorial.  In 48% of cases 
(12/25) DIC play a role in the genesis of renal failure and in 16% (4/25) of cases the 
etiology was DIC with hypotension and in 8% (2/25) was DIC with shock and 
capillary leak syndrome and in 4% (1/25) was DIC, shock and sepsis and in 24% 
(6/25) the etiology of renal failure was possible direct nephrotoxic action of venom. 
 A study of 8 cases of renal failure by Chugh KS, Bket BK and others 
regarding the etiology, Intravascular hemolysis and DIC contribute to 75% (6/8) and 
direct nephrotoxicity in 25% (2/8).  Studies of 45 cases of renal failure, by Chugh 
KS et al in 1984, the etiology of renal failure was multifactorial. (Hypotension, DIC, 
hemolysis and direct nephrotoxicity) A study of 13 cases in JIPMER, 61.35% (8/13) 
DIC with fibrinolysis was the etiological factor. 
Management aspects of renal failure  
 The supportive therapy in the form of careful rehydration, Inj. lasix, Inj. 
dopamine and blood transfusion were attempted. From the present study, it was 
observed that 14 cases out of 25 (56%) improved from renal failure by supportive 
therapy alone.  The patients not improved with supportive therapy were 11.  The 
hemodialysis was attempted in 7 out of 11 cases. 5 cases (71.4%) improved and 2 
cases (28.6%) not improved.  The above 2 cases was diagnosed as acute on CRF 
with the help of other investigations. 
 The peritoneal dialysis was attempted in 4 out of 11 cases.  One case not 
improved and diagnosed as acute on CRF with the help of other investigations.  3 
cases died of renal failure with other complications of envenomation. 
 It was observed by a study of 8 renal failure cases by Chugh et al 1975, by 
histopathologically, acute tubular necrosis in 52.5% (5/8) and bilateral acute cortical 
necrosis in 37.5% (3/8).  The (2/5) cases with ATN improved with conservative 
treatment and (3/5) improved with dialysis.  In bilateral ACN inspite of dialysis all 3 
cases died. By effective treatment oliguria resolved in 4-5 days. (chugh et al 1986) 
Complications of Haemotoxic envenomation  
 The study of the complications in 107 cases, it was found that ARF in 25 
cases (23.6%), hypotension and shock in 8 cases (7.48%), anaemia in 11 cases 
(10.28%). bleeding diathesis in 31 cases (28.97%), compartment syndrome in 5 
cases (4.67%), gangrene in 2 cases (1.87%) and sepsis, jaundice, stroke, ICH and 
vitreous haemorrhage in 1 case each (0.93%). 
Unusual complications of haemotoxic envenomation  
 In this study, there were 2 cases presented with unusual complications.  One 
case presented with ARF and left vitreous haemorrhage and intra retinal haematoma 
with probable etiology of DIC.  The second case presented with right hemiparasis  
 
 
UNUSUAL MANIFESTATION 
LEFT VITREOUS HAEMORRHAGE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUBCONJUNCTIVAL HAEMORRHAGE  ‘B’ SCAN (USG-LEFT EYE) SHOWS 
                       VITREOUS HAEMORRHAGE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HAEMATURIA     CT BRAIN SHOWS LEFT EYE 
       VITREOUS HAEMORRHAGE 
 
 
18- Year -old Shankar, presented with bleeding from multiple sites including 
Left Vitreous haemorrhage, and ARF.  He was treated with ASV, HD, his 
renal function recovered completely with partial recovery of left eye vision. 
 
 
 
 
UNUSUAL MANIFESTATIONS (STROKE) 
 
 
 
 
 
 
 
 
 
 
 
Right UMN Facial palsy – Deviation angle of mouth to left 
 
 
 
 
 
 
 
 
CT brain shows – left temparo parietal infarct 
 
 
 and right UMN facial palsy with in 4 hrs of viper bite with wernick’s aphasia and 
normal renal function, CT brain showed left temparo parietal infarct. 
Analysis of Death : 
Analysis of cause of death in Snake envenomation : 
 In this study of 107 cases, death occurred in 3 cases ie. 2.8%. Renal failure 
occurred in all the 3.  One case died due to ICH and one case died of circulatory 
failure and sepsis and one died due to circulatory failure and capillary leak 
syndrome. 
 A study of cause of death in 9 cases by Haudy DC 1986, there was prolonged 
hypotension and multiorgan failure in (5/9), Intestinal haemorrhage in (1/9) and 
unknown cause. (3/9) Another study showed that the distribution of cause of death 
by Aebuqueoge, Reberio (1988-93), it was acute renal failure (34-79%), shock (18-
41%) and sepsis. (18-41%) Among the renal failure of 23 cases, the incidence of 
death in ATN was 17.4% and bilateral ACN was 37.9% (Chugh and 
Chakaravarthi1984) 
Analysis of time interval of Death since bite  
 In this study, the time interval of death since bite ranges from 36hrs to 84hrs. 
Mean was 64hrs. The onset of death in viper bite occurs in a day to 3 days of bite. 
The previous  study available in relation with onset of death since bite was range 
from 1-6 days.(Banarji 1976) 29.4% death occurred in first 2 days.  67.6% of death 
occurred with in 5 days. (Aebuqueoge, Reberio 1988-93). 
 
 Analysis of Time interval for onset of treatment  
 In the death cases, the time interval for onset of treatment observed by present 
study ranges from 3-5 hrs. The mean was 4hrs.  A study of 9 death cases by Haudy 
DL 1986, the serotherapy (ASV) was administered within 4 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
1. In this study, the incidence of acute renal failure was 23.4% among the 107 
cases of snake envenomation (25/107). The etiology of renal failure was 
multifactorial.  The DIC and circulatory failure were the common etiological 
factors. DIC with capillary leak syndrome, DIC with sepsis and direct 
nephrotoxicity were considered as the other main etiological factors. 
2. The Incidence of renal failure was observed more with increase in the age of 
the victims and it was more in patients with delayed onset of treatment.  There 
was no difference in the incidence of renal failure among both sexes and 
tourniquet group and non-tourniquet group.  But, according to present study 
tourniquet application reduce the incidence of death. 
3. The Incidence of renal failure was more in the cases with preexisting severe 
anaemia (Hb < 8 g%) 
4. The incidence of renal failure was more in the cases with delayed onset of 
treatment with ASV since bite. The optimum dose of ASV used for 
normalization of clotting time from this study was 13 vials. 
5. Bleeding tendency occurred in 28.97% (31/107) cases.  In 96.8% of cases 
bleeding occurred within first 24 hours. From this study, the commonest type 
of bleeding observed was bleeding gums.  The haematamesis and haematuria 
were next common type of bleeding. 
6. The incidence of renal failure was more in the cases with bleeding diathesis 
(DIC and circulatory failure were the common etiological factors.) 
7. The incidence of renal failure was more in the cases with normal clotting 
time.  (Indicates the direct toxic effect of venom on the kidney). 
8. 64% of cases (16/25) the onset of renal failure was before 24 hrs.  Only in 
36% of cases (9/25) the onset was beyond 24 hrs. DIC with microthrombi in 
multiple sites including renal vasculature was the possible explanation for the 
early onset of renal failure. 
9. The supportive therapy with careful rehydration, and drugs such as lasix, 
dopamine and blood transfusion help in the recovery of renal failure in 56% 
of patients. (14/25).  Patients not improved with supportive therapy were 11.  
Hemodialysis was attempted in 7 out of 11 cases.  5/7 recovered and 2/7 not 
recovered and diagnosed as acute on CRF.  Peritoneal dialysis was attempted 
in 4 out of 11 cases.  1/4not recovered and diagnosed as acute on CRF.  3 / 4 
died of ARF with other complications of snakebite envenomation. 
10. The complications other than renal failure and hypotension were also noted.  
ICH, compartment syndrome, Jaundice, gangrene, sepsis also were observed 
in few cases. Unusual complications like vitreous haemorrhage and stroke 
were observed in this study. 
11. The incidence of death was 2.8% among 107 cases. The probable cause of 
death were DIC/ ARF/ ICH in one case, ARF / DIC / circulatory failure / 
sepsis in 2nd case and ARF / DIC / circulatory failure / capillary leak 
syndrome in 3rd case.  Thus, more than one etiological factor was observed. 
The death occurred within 84hrs.  In all 3 cases ASV administered within 5 
hours of bite. 
  
 
SUMMARY 
 
 The snakebite envenomation is preventable by the measure discussed earlier.  
The acute renal failure in snakebite is preventable to a certain extent.  The onset of 
renal failure in haemotoxic envenomation depends upon the factors like the severity 
of envenomation, the time of onset of serotherapy since bite, initial maximum and 
optimum dose of antisnake venom, degree of bleeding diathesis, degree of DIC and 
presence or absence of circulatory failure. 
 
 The correction of preexisting severe anaemia by blood transfusion, avoidance 
of nephrotoxic drugs, early normalization of clotting time is helpful in the prevention 
of onset and retard renal failure.  The role of heparin is still controversial. The 
supportive therapy, haemodialysis help to reduce mortality in renal failure among 
snake envenomation cases. 
 
 
 
 
 
 
SUGGESTIONS 
Snakebite is more common in rural and semi urban areas than in urban areas 
where snakes are more prevalent. The areas should be kept clean to prevent 
infiltration by snakes and rodents. Anti rodent measures should be vigorously carried 
out in all newly developing areas. 
 
Avoid nocturnal activity in the snake prevalent areas. No attempt should be 
made to kill the snakes on seeing them. With improving economic standard, farmers 
should be encouraged and motivated to use low cost foot wears and gloves and carry 
torch light while walking in snake infested areas. Piles of rubble, stones, bricks, 
termite mounds,deep vegetations thick foliage must be approached causiously 
specially more so after rains. Every effort should be made to prevent and treat 
anaemia.  
 
Dissemination of information regarding readily available effective treatment 
may drastically prevent the morbidity and mortality.  Over emphasis on first aid can 
be dangerous because it`s value is debatable and too much valuable time is wasted in 
it`s administration.  All primary health centers (PHC`s) should be provided with 
adequate anti snake venom and drugs for anti allergic measures. Species 
identification is not necessary since we are using polyvalent antivenom. ‘Snakebite is 
not synonymous with snakebite poisoning and all poisoning does not end in death if 
properly treated.’ 
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ACUTE RENAL FAILURE IN HAEMOTOXIC SNAKE ENVENOMATION 
PROFORMA 
1. Name  :    6. Case No.  : 
2. Age  :    7. I.P.No.   : 
3. Sex  :    8. Date of admission : 
4. Occupation :    9. Date of Discharge : 
5. Address :    10. Pre existing illness : 
                 (if any) 
 
11. General condition (Admission) 
  
Vomiting Abdominal colic Seizure Consciousness 
 
12. Vital signs (Admission) 
URINE PR BP RR TEMP 
COLOR OUTPUT 
      
 
                   Color  : N – Normal R – Red B – Brown   BL – Black 
13. Local examination 
 i)   Bite mark   
Yes / No Site No.of fang mark Time 
    
 
 ii) Tourniquet Yes / No 
 iii)   
Cellulitis Blisters Reginal adenitis 
   
14. Bleeding diathesis 
Onset bleeding (hrs) Type of bleeding 
  
Type of bleeding 
 1.  Bleeding gums  5.  Epitaxis 
 2. Haematuria  6.  Haemoptsis 
 3. Hae matamesis  7. Rectal bleeding 
 4. Malena   8. Multiple sites 
15. Clotting        N – Normal       P - Prolonged 
On admission On Treatment 
I   N / P 1.  N/P 
II   if P – (time interval 
since bite) 
II   If N – time interval since tmt 
start 
 
Day 1st  2nd   3rd  4th 5th Subsequently
Intake       
Output       
 
16. Investigations 
1.  Urine 
Albumin Sugar Deposits RBC’s Bs / Bp Others 
      
 
2.  Blood 
TC DC ESR BT HB % 
     
3.  
On set of Renal failure Blood On 
Admission 1st day 2nd day 3rd 4th 
Urea      
Creatinine      
RBS      
Electrolytes      
 
4)  
Peripheral smear (RBC – 
fragment) 
Platelet count Reticulocyte count 
   
 
5. Serum Fibrinogen 
6. LFT 
7. ECG 
8. Ultra sound Abdomen 
9. Others 
17.  Treatment  :   Onset of Treatment  (hrs)  : 
Anti snake 
venom (dose) 
Stratum 
(Vials) 
  Total dosage 
(Vials) 
  2nd 3rd  
     
 No. Of vials for CT to become Normal  :   How long  : 
18.   Renal failure 
 1) Time interval since bite to onset of renal failure (hrs) 
 2) 
 
 
3)Medical Treatment 
Inj. Lasix Inj. Dopamine Blood 
Transfusion 
Outcome 
Dose Days Dose Days  Improved Not 
improved 
    
 
3) Dialysis 
Peritoneal Dialysis 
No.of 
cycles 
How long Outcome 
   
 
19.  Other complication (if any) 
 (Compartment syndrome ICH, Sheehan’s syndrome cardio toxicity) 
20.   Period of Hospital stay : 
21.    
 
22. 
Cause of death date Renal failure Other cause 
   
Renal 
failure 
(cause) 
DIC Hypotension Direct 
Nephrotoxicity 
Intravascular 
Haemolysis 
Hemodialysis 
No.of 
cycles 
How long Outcome 
   
Recovered Morbidity Mortality Final Outcome 
   
KEY NOTES FOR MASTER CHART 
1. Serial No. 13. Urine output   -  UO   Normal - N 
Bile salt          - BS     Oliguria È 
Bile pigment  -  BP     Positive + 
2. Name 14. Haemoglobin in g % 
3. Age / Sex   - Male  -  M 
                     Female - F 
15. Urea / Creatinine  (mg / dl ) 
    Normal  -  N 
   Increased - Ç 
4. Site of Bite -  Foot -  F 
                      Hand  - H 
                      Back   -  B 
16. Platelet count   -   Normal  -  N 
                             Decreased - È 
5. Tourniquet     Yes  -  Y 
                       No   -  N 
17. Reticulocye count  -  Normal – N 
6. Clotting time      Prolonged  - P 
                           Normal   -  N 
18. Fibrinogen (mg %) 
7. Bleeding Diathesis 
                      Yes  -  Y 
                      No   -  N 
19. Peripheral smear  -  Fragmented RBC’s 
           Nil 
           Present   + 
8. Time of onset of bleeding 
(hours) 
20. Complete haemogram (CH) 
   Neutrophilia   -  Neu 
   Normal           - N  
9. Type of bleeding 
  Bleeding gums  -  BG 
  Haematamesis  -  HE 
  Haemoptysis  -  HU 
  Multiple sites -  MS 
  Malena       -  M 
21. Electro cardiogram  (ECG) 
 Normal       -    N 
Sinus bradycardia  -  SB 
Sinus tachycardia  -  ST 
Left bundle branch block -  LBBB 
Left ventricular hypertrophy – LVH 
Left anterior hemi block  - LAHB 
10. Onset of Treatment with ASV 
(hrs) 
22. Onset of Renal failure since bite (hours) 
11. Total vials used 23. 
12. Blood pressure in mm Hg 
    Normal  -  N 
    Decreased – È 
    Increased  - Ç 
 
Cause of Renal failure 
DIC – Disseminated intravascular              
coagulation 
AOC- Acute on chronic renal failure 
SS  -  Septic shock 
DT -  Direct Toxicity 
CS – Capillary leak syndrome 
 24. Supportive Treatment 
     Lasix 
     Dopamine   DOP 
     Blood transfusion  BT 
28. Period of hospital stay (days) 
25 Dialysis                             
Peritoneal dialysis- PD 
Hemodialysis   -  HD 
29. Cause of death 
26 No.of cycles 30. Time since bite (hours). 
27. Other complications 
  Compartment syndrome – CS 
  Gangrene 
  Stroke 
  Vitreous haemorrhage 
  
 
 
 
 
 
 
 
 
 
 
 
 
40 Year old Alagar, presented with right hemiparesis, right UMN facial palsy, 
Wernick’s aphasia with normal renal function 
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1 Mahalingam 35 
M 
F N P Y 6 BG 16 ½ 25 N N 9.6 N N N 100 Nil Neu T↓ 
V1-V4 
- - Nil - - Nil 5 - - 
2 Chittammal 40 
F 
F Y N Y 9 HE 8 10 N N 13.6 N N N 125 Nil Neu T↓ 
V1-V4 
- - Nil - - C.S 12 - - 
3 Guru samy 25 
M 
F Y P - - - 4 ½ 25 N N 10.2 N N N 125 Nil Neu N - - Nil - - Nil 4 - - 
4 Rogu mani 28 
F 
F Y P - - - 5 15 N N 9.6 N N N 125 Nil Neu N - - Nil - - Nil 4 - - 
5 Bala 
murugan 
35 
M 
F Y P - - - 2 ¼ 15 N N 13.4 N N N 125 Nil Neu N - - Nil - - Nil 4 - - 
6 Santhanam 55 
M 
F N P - - - 7 15 N N 10 N N N 150 Nil Neu ST↑ 
V1-V4 
- - Nil - - Nil 4 - - 
7 Selva mani 27 
F 
F Y P Y 1 BG 33 ½ 4 N N 8.4 ↑ ↓ N 100 + N SB 48 DIC Lasix - - Nil 5 - - 
8 Shankar 30 
M 
F Y P Y ½ BG 1 ½ 23 N N 9.6 ↑ ↓ N 115 Nil Neu N 1 
½ 
DIC - - - Nil 6 - - 
9 Karuppaiya 37 
M 
F Y P -   5 ½ 9 N N 9.4 N N N 75 Nil Neu N - - Nil - - Nil 3 - - 
10 Mayandi 42 
M 
F Y P -   15 5 N N 14.2 N N N 100 Nil Neu N - - Nil - - Nil 3 - - 
11 Karuppan 33 
M 
H Y P Y 4 ½ BG 6 15 N N 13.4 N N N 100 Nil N N - - Nil - - Nil 2 - - 
12 Periya  
samy 
57 
M 
F Y N -   7 ½ 10 N ↓ 13.4 N N N 150 Nil N N - - Nil - - Gan 
grene 
7 - - 
13 Sathiya 23 
F 
H N P Y 7 ½ HO 5 10 N N 10 N N N 75 Nil Neu N - - Nil - - Nil 3 - - 
14 Rajagam 45 
M 
F Y P -   6 10 N N 11.4 N N N 150 Nil Neu SB - - Nil - - Nil 5 - - 
15 Ravi 30 
M 
H N P -   6 10 N N 13.6 N N N 110 Nil N ST↓ 
V1-V6 
- - Nil - - Nil 3 - - 
16 Suresh 13 
M 
F Y P -   4 5 N N 12.4 N N N 125 Nil Neu N - - Nil - - Nil 3 - - 
17 Ramayee 50 
F 
H Y P Y 12 BG 5 5 ↑ ↓ 10.2 ↑ N N 125 Nil N ST 10 DIC 
AOC 
Lasix PD 
HD 
30 
12 
Nil 36 - - 
18 Aru mugam 35 
M 
F N P -   3 10 N N 11.8 N N N 150 Nil Neu N - - Nil - - Nil 2 - - 
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19 Ramar 13 
M 
F N P -   5 5 ↓ ↓ 8 ↑ ↓ N 125 Nil N S.T 16 DIC  
S S 
DOP PD 30 CS - DIC  
SS 
36 
20 Thiru mathi 17 
F 
F N P -   9 5 N N 10.8 N N N 125 Nil Neu N - - Nil - - Nil 3 - - 
21 Selva rani 19 
F 
F Y P Y ½ MS 2 ½ 15 N N 3.2 N N N 100 Nil N N - - Nil - - Nil 5 - - 
22 Kantha 
mmal 
20 
F 
F N P -   4 5 ↑ N 9.8 N N N 100 Nil N N - - Nil - - Nil 3 - - 
23 Devayee 55 
F 
F Y P Y ½ BG 2 15 ↓ ↓ 7 ↑ ↓ N 150 Nil N ST 28 DIC Nil HD 4 Nil 20 - - 
24 Alagu 25 
M 
F Y P Y 10 
½ 
BG 3 13 N N 14.6 N N N 150 Nil Neu ST - - Nil - - Nil 6 - - 
25 Ramasamy 20 
M 
F N P -   2 10 N N 13.4 N N N 100 Nil Neu N - - Nil - - Nil 2 - - 
26 Via kulam 37 
M 
H Y P -   6 10 N N 12.6 N N N 127 Nil Neu N - - Nil - - Nil 3 - - 
27 Periya  
samy 
42 
M 
F N P -   4 ½ 20 N N 12.8 N N N 150 Nil N N - - Nil - - Nil 3 - - 
28 Pakiri 43 
M 
H N P -   5 10 N N 10.6 N N N 125 Nil N N - - Nil - - Nil 3 - - 
29 Janaki 
raman 
30 
M 
F N N Y 6 HE 2 ½ 15 ↑ ↓ 14.8 ↑ N N 225 Nil Neu N 28 DT Nil - - Nil 6 - - 
30 Christober 
Muthiah 
26 
M 
F Y P - - - 3 ½ 5 N N 13.2 N N N 125 Nil N N - - Nil - - Nil 4 - - 
31 Muthu 
raman 
22 
M 
H Y P - - - 2 ½ 5 N N 12.8 N N N 125 Nil Neu N - - Nil - - Nil 2 - - 
32 Kannan 32 
M 
H Y P - - - 2 ¼ 20 N N 13.6 N N N 125 Nil Neu ST↑ 
Vi-V4 
- - Nil - - Nil 4 - - 
33 Sang 
Ammal 
55 
F 
F N N Y 2 HU 2 ¼ 10 N ↓ 11.4 ↑ N N 250 Nil N QS 
V1-V4 
18 DT Nil - - Nil 3 - - 
34 Thanga 
natchiyar 
55 
F 
F N P Y 4 BG 6 20 N N 7.4 N N N 150 Nil N N - - Nil - - Nil 3 - - 
35 Chell 
ammal 
20 
F 
F Y P - - - 11 10 N N 8.5 N N N 125 Nil Neu N - - Nil - - Nil 3 - - 
36 Arumugam 50 
F 
H Y P - - - 4 15 N N 11.4 N N N 150 Nil Neu N - - Nil - - Nil 3 - - 
37 Vellimalai 18 
M 
F Y P - - - 2 ½ 15 N N 10.4 N N N 160 Nil Neu N - - Nil - - Nil 3 - - 
38 Dhanus kodi 24 
M 
F Y P - - - 8 15 N N 10.4 N N N 125 Nil Neu SB - - Nil - - Nil 4 - - 
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39 Backiya 
Nathan 
75 
M 
H Y P - - - 11 15 ↑ N 10.2 N N N 150 Nil N LVHC - - Nil - - Nil 4 - - 
40 Muthu 
Krishnan 
14 
M 
F Y P - - - 10 15 N N 11.2 N N N 75 Nil Neu T ↓ 
V1-V3 
- - Nil - - Nil 2 - - 
41 Vellaiyan 60 
M 
F Y P - - - 4 10 N N 10.2 N N N 125 Nil Neu N - - Nil - - Nil 3 - - 
42 Selvam 25 
M 
F N P - - - 8 10 N N 10.6 N N N 125 Nil Neu ST - - Nil - - Nil 3 - - 
43 Muruga 
eswari 
19 
F 
F Y P - - - 8 15 N N 6.2 N N N 125 Nil N T ↓ 
V1-V6 
- - Nil - - CS 7 - - 
44 Rackkayee 60 
F 
F N P - - - 19 10 N N 11 N N N 150 Nil N ST - - Nil - - Nil 3 - - 
45 Priya 13 
F 
F Y P Y 12 BG 4 12 ↑ ↓ 7.2 ↑ ↓ N 125 Nil Neu SB 14 DIC Lasix HD 4 Nil 14 - - 
46 Bala 
murugan 
14 
M 
F Y P Y 19 M 7 5 N N 11.8 N N N 100 Nil N N - - Nil - - Nil 3 - - 
47 Venkatesh 21 
M 
F Y P - - - 1 14 ↑ N 13.2 N N N 75 Nil Neu Tall T 
V1-V6 
- - Nil - - Nil 3 - - 
48 Chinna 
adaikkan 
50 
M 
H Y P - - - 8 20 N N 11.2 N N N 75 Nil Neu N - - Nil - - Nil 3 - - 
49 Balu 40 
M 
F N P - - - 8 10 ↑ N 11.2 N N N 50 Nil Neu N - - Nil - - Nil 3 - - 
50 Chitra 25 
F 
F Y P - - - 7 ½ 5 N N 9.4 N N N 125 Nil Neu N - - Nil - - Nil 2 - - 
51 Muniyandi 60 
M 
F N P - - - 10 15 N N 11.4 N N N 125 Nil Neu SB - - Nil - - Nil 4 - - 
52 Meena 22 
F 
F Y P - - - 5 10 N N 8.8 N N N 100 Nil Neu N - - Nil - - Nil 3 - - 
53 Krishna 
mmal 
55 
F 
F Y P - - - 26 10 N N 8.4 N N N 75 Nil N N - - Nil - - Nil 3 - - 
54 Velammal 55 
F 
F N P Y 40 MS 60 15 N ↓ 5 ↑ ↓ N 75 + Neu LBBB 40 DIC BT - - Nil 5 - - 
55 Naina 
Mohamed 
42 
M 
F N P - - - 16 10 N N 13.6 N N N 100 Nil Neu N - - Nil - - Nil 3 - - 
56 Perumal 70 
M 
F N P Y 1 MS 8 ½ 10 N ↓ 11.6 N N N 100 Nil Neu N - - Nil - - Nil 2 - - 
57 Chandra 
sekar 
25 
M 
F Y P - - - 1 ½ 15 ↑ ↓ 13 ↑ ↓ N 75 Nil Neu N 54 DIC Lasix - - Nil 7 - - 
58 Jegadees 
waran 
20 
M 
F N P Y 4 HU 16 10 N ↓ 10.6 ↑ ↓ N 125 Nil Neu LAHB 
ST 
12 DIC Lasix - - Nil 5 - - 
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59 Pandi 45 
M 
F Y P - - - 2 ½ 22 N ↓ 11.8 N N N 175 Nil Neu N - - Nil - - Nil 3 - - 
60 Chitra 30 
F 
F N P - - - 14 10 N N 10.4 N N N 125 Nil Neu N - - Nil - - Nil 4 - - 
61 Saravana 
kumar 
15 
M 
F Y P - - - 3 25 N N 8.8 N N N 150 Nil Neu N - - Nil - - Nil 3 - - 
62 Pandi 30 
M 
F Y P Y 5 HE 10 25 ↓ ↓ 10.8 ↑ ↓ N 100 Nil Neu N 48 DIC 
shock 
CLS 
DOP 
BT 
- - Nil 8 - - 
63 Gomathy 50 
F 
H Y P - - - 24 10 N ↓ 10.2 N N N 75 Nil Neu N - - BT - - Nil 5 - - 
64 Pappa 35 
F 
F Y P Y 2 MS 3 35 ↓ ↓ 6.8 ↑ ↓ N 100 Nil N N 6 DIC 
shock 
BT - - Nil 12 - - 
65 Ravi 30 
M 
F Y P Y 2 MS 4 10 N ↓ 10.8 N N N 125 Nil N SB - - Nil - - Nil 2 - - 
66 Adham 40 
M 
H Y P - - - 3 10 ↑ N 10.2 N N N 175 Nil N SB - - Nil - - Gan 
grene 
6 - - 
67 Chinna raja 15 
M 
F Y P - - - 5 10 N N 10.6 N N N 150 Nil N N - - Nil - - Nil 2 - - 
68 Pandiya 
ammal 
30 
F 
F Y P - - - 4 20 N ↓ 9.8 N N N 150 Nil Neu N - - Nil - - Nil 4 - - 
69 Kannnan 32 
M 
F N P - - - 4 10 N ↓ 10.2 ↑ ↓ N 75 Nil N N 24 DIC DOP PD 20 ICH - DIC 
ICH 
72 
70 Chinnavar 31 
M 
F Y P Y 1 MS 5 ½ 15 ↑ ↓ 5.6 ↑ ↓ N 75 Nil Neu LAHB 36 DIC Lasix HD 2 CS 5 - - 
71 Amburose 70 
M 
F Y P Y 8 MS 3 11 ↑ ↓/+ 6 ↑ N N 125 Nil Neu SB 
LVH 
24 DIC 
AOC 
Lasix PD 
HD 
12 7 Nil 26 - - 
72 Rathina 
mala 
42 
F 
H Y P - - - 3 ½ 5 N N 10.8 N N N 100 Nil Neu ST - - Nil - - Nil 3 - - 
73 Rajendran 49 
M 
H Y P - - - 4 15 N N 11.2 N N N 75 Nil Neu Tall T 
V2-V6 
- - Nil - - Nil 3 - - 
74 Lakshma 
nan 
65 
M 
H Y P - - - 4 15 ↓ ↓ 7.4 ↑ ↓ N 75 Nil Neu S B 56 DIC 
Shock 
BT - - Nil 6 - - 
75 Anand 17 
M 
F N P Y 17 BG 4 15 N N 12.6 N N N 125 Nil Neu N - - Nil - - Nil 2 - - 
76 Mookkan 60 
M 
F N P - - - 6 ½ 15 ↓ ↓ 6.8 N N N 100 Nil Neu N - - DOP - - Nil 4 - - 
77 Ismail 29 
M 
F Y P - - - 4 10 N N 11.8 N N N 125 Nil Neu N - - Nil - - Nil 4 - - 
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78 Krishnan 51 
M 
F Y P Y 3 BG 9 ½ 15 N N 11.6 N N N 125 Nil Neu N - - Nil - - Nil 3 - - 
79 Rama 
lingam 
57 
M 
F Y P - - - 4 ½ 25 N N 15.2 N N N 100 Nil Neu SB - - Nil - - Nil 4 - - 
80 Vellaiy 
ammal 
23 
F 
F Y P - - - 20 10 N N 8.2 N N N 175 Nil Neu N - - Nil - - Nil 7 - - 
81 Mokka 
pillai 
35 
F 
F Y P Y 6 BG 6 10 N ↓ 9.2 N N N 125 Nil Neu N - - Nil - - Nil 5 - - 
82 Mani 
kandan 
22 
M 
F N P - - - 10 ½ 10 N N 12.4 N N N 250 Nil Neu N - - Nil - - Nil 5 - - 
83 Raman 55 
M 
F N P - - - 22 10 ↑ N 12.8 N N N 225 Nil N N - - Nil - - Nil 4 - - 
84 Perumal 17 
M 
F N P - - - 35 20 N ↓ 9.8 ↑ N N 200 Nil N N 24 DT Lasix - - Nil 5 - - 
85 Muthu 
Krishnan 
55 
M 
H Y P - - - 9 ½ 20 N ↓ 13.2 N N N 175 Nil N N - - Lasix - - Nil 5 - - 
86 Muthu 55 
M 
F Y P - - - 7 10 N ↓ 13.2 ↑ N N 225 Nil Neu N 24 DT Lasix - - Nil 5 - - 
87 Sathiya 24 
F 
F N P - - - 4 10 N N 10.2 N N N 175 Nil N N - - Nil - - Nil 3 - - 
88 Lakshmi 16 
F 
F N P - - - 6 15 N N 11.6 N N N 175 Nil N ST - - Nil - - Nil 2 - - 
89 Bala 
murugan 
13 
M 
F Y P - - - 3 9 N ↓ 9.2 ↑ ↓ N 75 Nil N N 16 DIC 
shock 
CLS 
DOP 
PT 
PD 24 Nil - DIC 
shock 
CLS 
84 
90 Ganapathy 60 
M 
F N P Y 4 HE 6 10 ↓ ↓ 10 ↑ ↓ N 100 Nil Neu SB 6 DIC 
Shock 
DOP - - Nil 4 - - 
91 Alagar samy 29 
M 
F N P - - - 2 ½ 9 N N 10.2 N N N 100 Nil N ST - - Nil - - Nil 3 - - 
92 Mani 37 
M 
F Y P - - - 6 ½ 5 N N 11.2 N N N 75 Nil N SB - - Nil - - Nil 3 - - 
93 Sahaya  
Raja 
45 
M 
H N N - - - 51 5 ↑ ↓ 7.8 ↑ N N 220 Nil N N 24 DT Lasix HD 4 Nil 30 - - 
94 Bala 
Krishnan 
50 
M 
F Y N - - - 27 5 N ↓ 9.4 ↑ N N 225 Nil N N 26 DT Lasix - - Nil 8 - - 
95 Guna 
sekaran 
46 
M 
Ba N P - - - 5 ½ 10 N N 10 N N N 100 Nil N ST - - Nil - - Nil 3 - - 
96 Mani 
kandan 
25 
M 
F N P - - - 12 10 N N 9.8 N N N 75 Nil N SB - - Nil - - Nil 2 - - 
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97 Asaiyan 16 
M 
F Y P - - - 6 10 N N 10.1 N N N 75 Nil N N - - Nil - - Nil 2 - - 
98 Kousalya 18 
F 
F Y P - - - 2 ½ 15 N N 8.8 N N N 50 Nil N N - - Nil - - Nil 4 - - 
99 Pappathy 32 
F 
F Y P Y 1 BG 2 ½ 20 N N 9.7 N N N 100 Nil N N - - Nil - - Nil 3 - - 
100 Dhava pandi 24 
M 
H N P - - - 7 ½ 10 N N 9.2 N N N 125 Nil N SB - - Nil - - Nil 2 - - 
101 Bala 
murugan 
32 
M 
F Y P - - - 8 ½ 15 N N 10.6 N N N 100 Nil N Tall T 
V2-V4 
- - Nil - - Nil 2 - - 
102 Tamilarasi 17 
F 
F Y P Y 12 M 4 ½ 10 ↑ ↓ 6 ↑ N N 125 Nil N ST 16 DIC 
AOC 
Lasix PD 24 C.S. 13 - - 
103 Sandana 
karuppu 
27 
M 
F N P - - - 6 10 N N 10.2 N N N 100 Nil N N - - Nil - - Nil 3 - - 
104 Mani 
kandan 
24 
M 
F N P - - - 6 ½ 10 N N 11.2 N N N 125 Nil N N - - Nil - - Nil 5 - - 
105 Alagar 40 
M 
F N P Y 3 BG 15 ½ 15 N N 10.6 N ↓ N 125 Nil Neu N - - BT - - Stroke 12 - - 
106 Shankar 18 
M 
F Y P Y 4 MS 12 20 ↓ ↓ 10.2 ↑ ↓ N 125 Nil N N 16 DIC 
Shock 
DOP 
BT 
HD 6 Vit.Hge 14 - - 
107 Karthick 21 
M 
F Y P - - - 5 10 N N 10.6 N N N 150 Nil N N - - Nil - - Nil 4 - - 
 
 
 
 
 
 
